

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 28 PATDPAFULL - New display fields provide for legal status  
data from INPADOC  
NEWS 4 FEB 28 BABS - Current-awareness alerts (SDIs) available  
NEWS 5 MAR 02 GBFULL: New full-text patent database on STN  
NEWS 6 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced  
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded  
NEWS 8 MAR 22 KOREAPAT now updated monthly; patent information enhanced  
NEWS 9 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY  
NEWS 10 MAR 22 PATDPASPC - New patent database available  
NEWS 11 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags  
NEWS 12 APR 04 EPFULL enhanced with additional patent information and new  
fields  
NEWS 13 APR 04 EMBASE - Database reloaded and enhanced  
NEWS 14 APR 18 New CAS Information Use Policies available online  
NEWS 15 APR 25 Patent searching, including current-awareness alerts (SDIs),  
based on application date in CA/CAPLUS and USPATFULL/USPAT2  
may be affected by a change in filing date for U.S.  
applications.  
NEWS 16 APR 28 Improved searching of U.S. Patent Classifications for  
U.S. patent records in CA/CAPLUS  
NEWS 17 MAY 23 GBFULL enhanced with patent drawing images  
NEWS 18 MAY 23 REGISTRY has been enhanced with source information from  
CHEMCATS  
NEWS 19 JUN 06 The Analysis Edition of STN Express with Discover!  
(Version 8.0 for Windows) now available  
NEWS 20 JUN 13 RUSSIAPAT: New full-text patent database on STN  
NEWS 21 JUN 13 FRFULL enhanced with patent drawing images  
NEWS 22 JUN 27 MARPAT displays enhanced with expanded G-group definitions  
and text labels  
NEWS 23 JUL 01 MEDICONF removed from STN  
NEWS 24 JUL 07 STN Patent Forums to be held in July 2005  
NEWS 25 JUL 13 SCISEARCH reloaded  
NEWS 26 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
  
NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information

08/09/2005 10698009.trn

NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:42:14 ON 09 AUG 2005

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:42:30 ON 09 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2005 HIGHEST RN 859027-58-0

DICTIONARY FILE UPDATES: 8 AUG 2005 HIGHEST RN 859027-58-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*

08/09/2005 10698009.trn


\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10698009.str



chain nodes :

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31  
33

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

2-28 4-21 7-33 8-11 9-20 11-12 12-13 13-14 13-29 14-15 15-16 15-30  
16-17 17-18 17-19 19-31 21-22 22-23 22-26 23-24 23-27 24-25

ring bonds :

1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10

exact/norm bonds :

2-28 4-21 13-29 15-30 17-18 17-19 21-22 22-26

exact bonds :

1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 7-33 8-9 8-11 9-10 9-20 11-12  
12-13 13-14 14-15 15-16 16-17 19-31 22-23 23-24 23-27 24-25

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS  
10698009.trn Page 3 12:03 24:CLASS 25:CLASS 26:CLASS  
27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 33:CLASS

Stereo Bonds:

11-8 (Single Wedge).  
20-9 (Single Wedge).  
27-23 (Single Wedge).  
28-2 (Single Wedge).  
29-13 (Single Wedge).  
33-7 (Single Wedge).

Stereo Chiral Centers:

2 (Parity=Odd)  
7 (Parity=Even)  
8 (Parity=Odd)  
9 (Parity=Odd)  
13 (Parity=Odd)  
23 (Parity=Odd)

Stereo RSS Sets:


Type=Relative (Default). 6 Nodes= 2 7 8 9 13 23

L1 STRUCTURE UPLOADED

=> D L1

L1 HAS NO ANSWERS

L1 STR



08/09/2005 10698009.trn

Structure attributes must be viewed using STN Express query preparation.

=> S L1

SAMPLE SEARCH INITIATED 11:42:53 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 7 TO 298  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> S L1 SSS FULL

FULL SEARCH INITIATED 11:43:01 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 315 TO ITERATE


100.0% PROCESSED 315 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

L3 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10698009a.str



chain nodes :

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 32

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

2-28 4-21 7-32 8-11 9-20 11-12 12-13 13-14 13-29 14-15 15-16 15-30  
16-17 17-18 17-19 21-22 22-23 22-26 23-24 23-27 24-25

10698009.trn

Page 5

12:03

08/09/2005 10698009.trn

ring bonds :

1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10

exact/norm bonds :

2-28 4-21 13-29 15-30 17-18 17-19 21-22 22-26

exact bonds :

1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 7-32 8-9 8-11 9-10 9-20 11-12  
12-13 13-14 14-15 15-16 16-17 22-23 23-24 23-27 24-25

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS  
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS  
27:CLASS 28:CLASS 29:CLASS 30:CLASS 32:CLASS

Stereo Bonds:

11-8 (Single Wedge).  
20-9 (Single Wedge).  
27-23 (Single Wedge).  
28-2 (Single Wedge).  
29-13 (Single Wedge).  
32-7 (Single Wedge).

Stereo Chiral Centers:

2 (Parity=Odd)  
7 (Parity=Even)  
8 (Parity=Odd)  
9 (Parity=Odd)  
13 (Parity=Odd)  
23 (Parity=Odd)

Stereo RSS Sets:

Type=Relative (Default). 6 Nodes= 2 7 8 9 13 23

L4 STRUCTURE UPLOADED


=> d 14

L4 HAS NO ANSWERS

L4 STR

08/09/2005

10698009.trn



Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 11:44:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 24 TO ITERATE

100.0% PROCESSED 24 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 187 TO 773

PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 sss full

FULL SEARCH INITIATED 11:44:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 512 TO ITERATE

100.0% PROCESSED 512 ITERATIONS

SEARCH TIME: 00.00.01

67 ANSWERS

L6 67 SEA SSS FUL L4

=> FIL HCAPLUS

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

08/09/2005 10698009.trn

FULL ESTIMATED COST

323.52 323.73

FILE 'HCAPLUS' ENTERED AT 11:44:36 ON 09 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2005 VOL 143 ISS 7  
FILE LAST UPDATED: 8 Aug 2005 (20050808/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> ~~s 16~~  
L7 2139 L6

=> FIL CAPLUS  
COST IN ~~U.S.~~ DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
2.45	326.18

FILE 'CAPLUS' ENTERED AT 11:44:56 ON 09 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2005 VOL 143 ISS 7  
FILE LAST UPDATED: 8 Aug 2005 (20050808/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 16



08/09/2005 10698009.trn

L8 2139 L6

=> FIL HCAPLUS  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.45	326.63

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 11:45:07 ON 09 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2005 VOL 143 ISS 7  
FILE LAST UPDATED: 8 Aug 2005 (20050808/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 11:42:14 ON 09 AUG 2005)

FILE 'REGISTRY' ENTERED AT 11:42:30 ON 09 AUG 2005

L1 STRUCTURE UPLOADED  
L2 0 S L1  
L3 0 S L1 SSS FULL  
L4 STRUCTURE UPLOADED  
L5 0 S L4  
L6 67 S L4 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:44:36 ON 09 AUG 2005

L7 2139 S L6

FILE 'CAPLUS' ENTERED AT 11:44:56 ON 09 AUG 2005

L8 2139 S L6

FILE 'HCAPLUS' ENTERED AT 11:45:07 ON 09 AUG 2005

=> s 17 and composition  
638314 COMPOSITION  
288523 COMPOSITIONS  
921226 COMPOSITION  
(COMPOSITION OR COMPOSITIONS)  
1351441 COMPN  
544323 COMPNS  
1655583 COMPN

(COMPONENT OR COMPONENTS)  
2095452 COMPOSITION  
(COMPOSITION OR COMPONENT)

L9 327 L7 AND COMPOSITION

=> s 19 and sodium  
989801 SODIUM  
34 SODIUMS  
989810 SODIUM  
(SODIUM OR SODIUMS)

L10 132 L9 AND SODIUM

=> s 110 and pravastatin  
2420 PRAVASTATIN  
1 PRAVASTATINS  
2420 PRAVASTATIN  
(PRAVASTATIN OR PRAVASTATINS)

L11 127 L10 AND PRAVASTATIN

=> s 111 and hmg-coA  
9504 HMG  
101 HMGS  
9528 HMG  
(HMG OR HMGS)

41216 COA  
918 COAS  
41395 COA  
(COA OR COAS)

6052 HMG-COA  
(HMG(W) COA)

L12 52 L11 AND HMG-COA

=> s 112 and reductase  
82330 REDUCTASE  
6290 REDUCTASES  
83384 REDUCTASE  
(REDUCTASE OR REDUCTASES)

L13 51 L12 AND REDUCTASE

=> s 113 and inhibitor  
480825 INHIBITOR  
494689 INHIBITORS  
766615 INHIBITOR  
(INHIBITOR OR INHIBITORS)

L14 51 L13 AND INHIBITOR

=> s 114 and purified  
407513 PURIFIED  
2 PURIFIEDS  
407515 PURIFIED  
(PURIFIED OR PURIFIEDS)

L15 0 L14 AND PURIFIED

=> s 114 and impurity  
154887 IMPURITY  
191116 IMPURITIES  
285990 IMPURITY  
(IMPURITY OR IMPURITIES)

L16 0 L14 AND IMPURITY

08/09/2005 10698009.trn

=> s l14 and py<=1998  
18939279 PY<=1998  
L17 6 L14 AND PY<=1998

=> s l4 and p/dt

**REGISTRY INITIATED**

Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 11:51:37 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 24 TO ITERATE

100.0% PROCESSED 24 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 187 TO 773  
PROJECTED ANSWERS: 0 TO 0

L18 0 SEA SSS SAM L4

L19 0 L18

4780857 P/DT  
L20 0 L19 AND P/DT

=> d his

(FILE 'HOME' ENTERED AT 11:42:14 ON 09 AUG 2005)

FILE 'REGISTRY' ENTERED AT 11:42:30 ON 09 AUG 2005

L1 STRUCTURE UPLOADED  
L2 0 S L1  
L3 0 S L1 SSS FULL  
L4 STRUCTURE UPLOADED  
L5 0 S L4  
L6 67 S L4 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:44:36 ON 09 AUG 2005

L7 2139 S L6

FILE 'CAPLUS' ENTERED AT 11:44:56 ON 09 AUG 2005

L8 2139 S L6

FILE 'HCAPLUS' ENTERED AT 11:45:07 ON 09 AUG 2005

L9 327 S L7 AND COMPOSITION  
L10 132 S L9 AND SODIUM  
L11 127 S L10 AND PRAVASTATIN  
L12 52 S L11 AND HMG-COA  
L13 51 S L12 AND REDUCTASE

08/09/2005 10698009.trn

L14 51 S L13 AND INHIBITOR  
L15 0 S L14 AND PURIFIED  
L16 0 S L14 AND IMPURITY  
L17 ~~6 S L14 AND PY<=1998~~  
S L4 AND P/DT

FILE 'REGISTRY' ENTERED AT 11:51:36 ON 09 AUG 2005

L18 0 S L4

FILE 'HCAPLUS' ENTERED AT 11:51:37 ON 09 AUG 2005

L19 0 S L18

L20 0 S L19 AND P/DT

=> s l14 and pc/us

'US' IS NOT A VALID FIELD CODE

0 PC/US

L21 0 L14 AND PC/US

=> s l14 and us/pc

1394437 US/PC

L22 32 L14 AND US/PC

=> d l17 ibib abs hitstr tot

L17 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:98321 HCAPLUS

DOCUMENT NUMBER: 128:196661

TITLE: Antithrombotic and antiatherogenic pharmaceutical  
**composition** including a thienopyridine  
derivative and an **HMG-CoA**  
**reductase inhibitor**

INVENTOR(S): Daste, Georges; Herbert, Jean-Marc

PATENT ASSIGNEE(S): Sanofi, Fr.

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804259	A1	<u>19980205</u>	WO 1997-FR1353	19970721 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2751540	A1	19980130	FR 1996-9474	19960726 <--
FR 2751540	B1	19981016		
ZA 9706247	A	19990115	ZA 1997-6247	19970715
CA 2261099	AA	19980205	CA 1997-2261099	19970721 <--
CA 2261099	C	20030415		
AU 9738526	A1	19980220	AU 1997-38526	19970721 <--
AU 725949	B2	20001026		
EP 914124	A1	19990512	EP 1997-935593	19970721

EP 914124	B1	20040121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9710560	A	19990817	BR 1997-10560	19970721
CN 1228698	A	19990915	CN 1997-197539	19970721
CN 1109547	B	20030528		
JP 2000500781	T2	20000125	JP 1998-508545	19970721
JP 3553610	B2	20040811		
NZ 333826	A	20000929	NZ 1997-333826	19970721
RU 2176504	C2	20011210	RU 1999-103623	19970721
EE 3853	B1	20021015	EE 1999-28	19970721
AT 258052	E	20040215	AT 1997-935593	19970721
PT 914124	T	20040531	PT 1997-935593	19970721
ES 2214632	T3	20040916	ES 1997-935593	19970721
CZ 294664	B6	20050216	CZ 1999-176	19970721
PL 188739	B1	20050429	PL 1997-331339	19970721
KR 2000029484	A	20000525	KR 1999-700501	19990122
<u>US 6218403</u>	B1	<u>20010417</u>	US 1999-230299	19990122
NO 9900321	A	19990322	NO 1999-321	19990125
HK 1019405	A1	20031017	HK 1999-104578	19991101
PRIORITY APPLN. INFO.:			FR 1996-9474	A 19960726
OTHER SOURCE(S):			WO 1997-FR1353	W 19970721
GI			MARPAT 128:196661	




- AB A pharmaceutical composition containing (a) a thienopyridine derivative (I; R = H, Cl-4 alkoxy carbonyl) or a pharmaceutically acceptable salt thereof; and (b) an **HMG-CoA-reductase inhibitor**, is disclosed. A combination of 5 mg/kg clopidogrel and 5 mg/kg simvastatin had synergistic effect and inhibited the formation of thrombose by 72% in rabbits. A 2-layered pharmaceutical tablet contained ticlopidine hydrochloride 200.00, microcryst. cellulose 69.88, maize starch 31.20, polyvidone 6.24, citric acid 3.12, stearic acid 0.78, magnesium stearate 0.78 mg in the first layer and simvastatin 20.00, butyldroxanisole 0.04, ascorbic acid 5.00, citric acid 2.50, microcryst. cellulose 10.00, maize starch 20.00, lactose 141.50, magnesium stearate 1.00, methylhydroxy Pr cellulose 1.65, hydroxypropyl cellulose 1.65, titanium dioxide 1.50, talc 0.60, yellow ferric oxide 0.092, and red ferric oxide 0.023 mg in the second layer.
- IT **81131-70-6, Pravastatin Sodium**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antithrombotic and antiatherogenic pharmaceutical **composition** including thienopyridine derivative and **HMG-CoA reductase inhibitor**)

RN 81131-70-6 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:315691 HCAPLUS

DOCUMENT NUMBER: 126:334419

TITLE: Pharmaceutical **compositions** for preventing a second heart attack containing an **HMG CoA reductase inhibitor**

INVENTOR(S): Olukotun, Adeove Y.; Alexander, John C.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: U.S., 8 pp., Cont.-in-part of U.S. Ser. No. 824,679, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5622985	A	19970422	US 1995-424984	19950419 <--
CA 2172884	AA	19961020	CA 1996-2172884	19960328 <--
EP 738512	A1	19961023	EP 1996-106104	19960418 <--
EP 738512	B1	20030702		

R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

AU 9650741	A1	19961031	AU 1996-50741	19960418 <--
AU 715181	B2	20000120		
AT 244006	E	20030715	AT 1996-106104	19960418
PT 738512	T	20031128	PT 1996-106104	19960418
ES 2202393	T3	20040401	ES 1996-106104	19960418
JP 08291082	A2	19961105	JP 1996-98084	19960419 <--

PRIORITY APPLN. INFO.:

US 1990-536367	B1	19900611
US 1992-824679	B2	19920123
US 1995-424984	A	19950419


AB A pharmaceutical **compns.** is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an **HMG CoA reductase inhibitor** such as **pravastatin (I)**, alone or in combination with an **ACE inhibitor**. A tablet contained I 7, lactose 67, microcryst. cellulose 20, croscarmellose **sodium** 2, magnesium stearate 2, and magnesium oxide 3 parts.

IT **81093-37-0, Pravastatin**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical **compns.** for preventing second heart attack containing **HMG CoA reductase inhibitor**)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:192587 HCAPLUS

DOCUMENT NUMBER: 126:258927

TITLE: Effects of low-dose **pravastatin sodium** on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year

AUTHOR(S): Harsch, Michael; Braesen, Jan Hinrich; Niendorf, Axel

CORPORATE SOURCE: Institute Pathology, University Hamburg, Hamburg, 20246, Germany

SOURCE: Atherosclerosis (Shannon, Ireland) (1997), 128(2), 139-147

CODEN: ATHSBL; ISSN: 0021-9150

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The aim of this study was to evaluate the cholesterol-lowering and antiatherosclerotic effect of the **HMG-CoA reductase inhibitor pravastatin sodium** at a dosage comparable to human therapy. Twelve heterozygous WHHL rabbits (13 mo old) were fed 100 g per day of a low cholesterol (0.03%) enriched diet for 12 mo. Six of these animals also received **pravastatin sodium** at a daily dose of 1 mg/kg body weight (verum group). In the verum group, total plasma cholesterol levels were lower by 47% ( $P < 0.05$ )

and relative aortic plaque volume (% ratio of total plaque volume to the aortic lumen) was reduced by 78% ( $P < 0.05$ ), when compared to the control group. Plaque **composition** was analyzed at 30 cross-sectional levels of the entire aortic wall using a grid window. Compared to the control group, the plaque type, in terms of architecture and **composition**, was altered as follows: lesions in the verum group had no confluent atheromatous cores and showed a pattern of a diffuse mixture of the main plaque components with a decreased relative content of necrosis (-44%) and an increased relative content of smooth muscle cells (+19%), whereas the relative content of macrophage-derived foam cells and collagen were nearly unaffected. Furthermore, a similar plaque volume and type was observed in animals with comparable cholesterol profiles. There was no histol. evidence for structurally damaging effects of **pravastatin sodium** on the arterial wall. We conclude that **pravastatin sodium** reduces total plasma cholesterol levels in this animal model, thereby leading to smaller plaques and a different plaque type.

IT 81093-37-0, **Pravastatin**


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(effects of low-dose **pravastatin sodium** on plasma cholesterol levels and aortic atherosclerosis in heterozygous WHHL rabbits fed low cholesterol diet)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:178769 HCAPLUS

DOCUMENT NUMBER: 126:176899

TITLE: Synergistic combination comprising an insulin sensitizer and a **HMG-CoA reductase inhibitor** for treating arteriosclerosis

INVENTOR(S): Tsujita, Yoshio; Horikoshi, Hiroyoshi; Shiomi, Masashi; Ito, Takashi

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:




PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 753298	A1	19970115	EP 1996-304924	19960703 <--
EP 753298	B1	20011121		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2180296	AA	19970104	CA 1996-2180296	19960702 <--
NO 9602784	A	19970106	NO 1996-2784	19960702 <--
AU 9656261	A1	19970116	AU 1996-56261	19960702 <--
AU 706628	B2	19990617		
JP 09071540	A2	19970318	JP 1996-172137	19960702 <--
JP 3651816	B2	20050525		
US 5798375	A	19980825	US 1996-676090	19960702 <--
IL 118778	A1	19990714	IL 1996-118778	19960702
RU 2158607	C2	20001110	RU 1996-112769	19960702
TW 474809	B	20020201	TW 1996-85107984	19960702
ZA 9605650	A	19970127	ZA 1996-5650	19960703 <--
CN 1148492	A	19970430	CN 1996-112170	19960703 <--
CN 1089584	B	20020828		
CZ 286832	B6	20000712	CZ 1996-1982	19960703
AT 209046	E	20011215	AT 1996-304924	19960703
ES 2165474	T3	20020316	ES 1996-304924	19960703
PT 753298	T	20020328	PT 1996-304924	19960703
US 6159997	A	20001212	US 1998-61446	19980416
HK 1011928	A1	20020628	HK 1998-113080	19981210
JP 2004075691	A2	20040311	JP 2003-359698	20031020
JP 2004250455	A2	20040909	JP 2004-96229	20040329
PRIORITY APPLN. INFO.:			JP 1995-167291	A 19950703
			JP 1996-172137	A3 19960702
			US 1996-676090	A3 19960702
AB	A combination of 1 or more HMG-CoA reductase inhibitors (e.g., pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with 1 or more insulin sensitizers (e.g., troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminoxy]ethoxy}benzyl}thiazolidine-2,4-dione) exhibits a synergistic effect and is better at prevention and/or treatment of arteriosclerosis and/or xanthoma than is either of the components of the combination alone. Thus, pravastatin sodium 0.5, troglitazone 20, Crospovidone 1.5, and Na lauryl sulfate 0.2 g were blended and the mixture was divided among 100 capsules, each containing 5 mg pravastatin sodium and 200 mg troglitazone. The preparation of some thiazolidine-2,4-diones is reported.			
IT	81093-37-0, Pravastatin 81131-70-6, Pravastatin sodium RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (synergistic composition containing insulin sensitizer and HMG-CoA reductase inhibitor for treatment of arteriosclerosis)			
RN	81093-37-0 HCAPLUS			
CN	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (8R,8R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)			

Absolute stereochemistry.



RN 81131-70-6 HCAPLUS  
 CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L17 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1996:701531 HCAPLUS  
 DOCUMENT NUMBER: 125:339030  
 TITLE: Use of **HMG CoA reductase inhibitor** to prevent second heart attack  
 INVENTOR(S): Olukotun, Adeoye Y.; Alexander, John C.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: Eur. Pat. Appl., 11 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 738512	A1	19961023	EP 1996-106104	19960418 <--
EP 738512	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5622985	A	19970422	US 1995-424984	19950419 <--
PRIORITY APPLN. INFO.:			US 1995-424984	A 19950419

US 1990-536367

B1 19900611

US 1992-824679

B2 19920123

AB A method is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an **HMG CoA reductase inhibitor** such as **pravastatin**, alone or in combination with an **ACE inhibitor**. Tablets were formulated containing **pravastatin** 7, **lactose** 67, microcryst. cellulose 20, croscarmellose **sodium** 2, magnesium stearate 1, and magnesium oxide 3 parts by weight

IT 81093-37-0, **Pravastatin**


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**HMG CoA reductase inhibitor** to prevent second heart attack and pharmaceutical **compns.** containing **HMG CoA reductase inhibitor** and other ingredients)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (1R,2R,6R,7R,8R,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:497325 HCAPLUS

DOCUMENT NUMBER: 125:151167

TITLE: A controlled release drug delivery device comprising two-layered core and coating

INVENTOR(S): Rork, Gerald S.; Pipkin, James D.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9619201	A1	19960627	WO 1995-US16530	19951218 <--
W:	AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			

US 5582838	A	19961210	US 1994-363451	19941222 <--
CA 2206211	AA	19960627	CA 1995-2206211	19951218 <--
AU 9644726	A1	19960710	AU 1996-44726	19951218 <--
AU 693313	B2	19980625		
EP 801560	A1	19971022	EP 1995-943469	19951218 <--
EP 801560	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
CN 1171048	A	19980121	CN 1995-196988	19951218 <--
CN 1081916	B	20020403		
HU 77370	A2	19980330	HU 1997-1914	19951218 <--
JP 11509829	T2	19990831	JP 1995-519938	19951218
SK 281224	B6	20010118	SK 1997-805	19951218
RU 2168330	C2	20010610	RU 1997-112378	19951218
PL 183615	B1	20020628	PL 1995-320792	19951218
CZ 290802	B6	20021016	CZ 1997-1895	19951218
AT 244001	E	20030715	AT 1995-943469	19951218
PT 801560	T	20031031	PT 1995-943469	19951218
ES 2201133	T3	20040316	ES 1995-943469	19951218
FI 9702586	A	19970617	FI 1997-2586	19970617 <--
NO 9702880	A	19970620	NO 1997-2880	19970620 <--
PRIORITY APPLN. INFO.:			US 1994-363451	A 19941222
			WO 1995-US16530	W 19951218

AB A device disclosed for the controlled delivery of a beneficial agent consisting of (1) a core comprising at least two layers, wherein at least one layer comprises a beneficial agent and a polymer which forms microscopic gel beads upon hydration and at least one layer which comprises a polymer which forms microscopic gel beads upon hydration; and (2) an impermeable, insol. coating which adheres to and surrounds the core and contains apertures which provide an area for the hydration and release of the microscopic gel beads. A two-layered core contained lovastatin (I) 40, Carbopol 974P 16, trisodium citrate 32, and lactose 16 mg/layer in the first layer and Avicel PH101 20, Carbopol 974P 8, trisodium citrate 16, and lactose 8 mg/layer in the second layer. The cores were coated with a solution of cellulose acetate butyrate 20, and triethylcitrate 3 parts in a solution of acetone:ethanol (3:1) and sprayed onto the cores to a thickness of 100µm and two holes were drilled in the face of the device. The release profile of the two layer device were significantly improved over the single **composition** core, in that the last 20% of I was released at a more constant rate and greater than 95% of the I content was released in <20 h.


IT **81093-37-0, Pravastatin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(controlled release drug delivery device comprising two-layered core and coating)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=&gt; d 122 ibib abs hitstr tot

L22 ANSWER 1 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2005:411059 HCAPLUS  
 DOCUMENT NUMBER: 142:469260  
 TITLE: HDL-boosting combination therapy complexes  
 INVENTOR(S): Tunac, Josefino B.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 15 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101561	A1	20050512	US 2004-983836	20041108 <--
WO 2005046662	A2	20050526	WO 2004-US37324	20041108
WO 2005046662	A3	20050623		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-518091P P 20031107

AB A pharmaceutical **composition** including therapeutically effective amts. of at least one **HMG-CoA reductase inhibitor** present as a dyhydroxyacid salt and at least one addnl. therapeutic agent is claimed. Dehydroxy acid salt of **sodium lovastatin (I)** was prepared and its antilipidemic activity was studied in hamster. A repeat side-by-side comparison between I and Lipitor at 5-20 mg dose range confirmed the effectiveness of I in decreasing LDL, moreover, I was effective at a dose as low as 5 mg.


IT **81093-37-0, Pravastatin**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (HDL-boosting combination therapy complexes)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (6R,8R,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 2 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:346827 HCAPLUS

DOCUMENT NUMBER: 142:397743

TITLE: A solid dosage form comprising a fibrate and a statin

INVENTOR(S): Holm, Per; Norling, Tomas

PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005034908	A2	20050421	WO 2004-DK668	20041001
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005096390	A1	20050505	US 2004-988818	20041115 <--
US 2005096391	A1	20050505	US 2004-988829	20041115 <--
PRIORITY APPLN. INFO.:			DK 2003-1503	A 20031010
			DK 2004-464	A 20040323
			WO 2004-DK668	A2 20041001

AB The present invention relates to pharmaceutical **comps.** in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a **HMG CoA reductase inhibitors**). The **comps** are manufactured without any need of addition of water or an aqueous medium and wherein at least 80% of the active substances (i.e., the fibrate and the

statin) are present in the **composition** in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration. Thus, tablets contained fenofibrate 160.09, PEG 208.12, Poloxamer-188 89.19, lactose 356.51, and Mg stearate 4.09 mg.


IT **81093-37-0, Pravastatin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solid dosage form comprising fibrate and statin)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:995960 HCAPLUS

DOCUMENT NUMBER: 141:416027

TITLE: Combination comprising S-[2-([1-(2-ethylbutyl)cyclohexyl]carbonyl)amino]phenyl] 2-methylpropanethioate and a **HMG CoA reductase inhibitor**

INVENTOR(S): Urata, Yasuo; Hoshino, Shoji; Kawamura, Hitoshi; Okamoto, Hiroshi; Furukawa, Noboru

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098583	A1	20041118	WO 2004-US13633	20040430
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005020668	A1	20050127	US 2004-835916	20040430 <--

PRIORITY APPLN. INFO.:

US 2003-467418P	P	20030502
US 2003-471495P	P	20030516
US 2003-477372P	P	20030610
US 2004-534856P	P	20040108

AB The invention provides a combination comprising (a) S-[2-([1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate (I) or prodrug of the active form thereof, and (b) at least one **HMG**

**CoA reductase inhibitor**. Also provided are a pharmaceutical **composition**, package, and a kit comprising the the active ingredients, as well as a method for treatment and prophylaxis of a cardiovascular disorder involving the use of the the active ingredients. Thus, the combination of I and a **HMG CoA reductase inhibitor** decreased the atherogenic index in rabbits on a high cholesterol diet.

IT 81093-37-0, Pravastatin 81131-70-6, Pravastatin sodium 791595-03-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination comprising (ethylbutyl)cyclohexylcarbonylaminophenyl methylpropanethioate and **HMG CoA reductase inhibitor**)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 81131-70-6 HCAPLUS


CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



08/09/2005

10698009.trn




● Na

RN 791595-03-4 HCAPLUS  
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR)-, mixt. with S-[2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl] 2-methylpropanethioate (9CI) (CA INDEX NAME)

CM 1

CRN 211513-37-0

CMF C23 H35 N O2 S




CM 2

CRN 81131-70-6

CMF C23 H36 O7 . Na

Absolute stereochemistry.



● Na

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 4 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:589248 HCAPLUS

DOCUMENT NUMBER: 141:140474

TITLE: Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds

INVENTOR(S): Sher, Philip M.; Ellsworth, Bruce A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 43 pp.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004142938	A1	20040722	US 2003-712823	20031113 <--
PRIORITY APPLN. INFO.:			US 2002-426465P	P 20021114
OTHER SOURCE(S):	MARPAT	141:140474		
GI				




I



= W1



= W2



= W3

AB Prodrugs of glycogen phosphorylase inhibiting compds. are provided, said prodrug compds.,  $G(-O_2CR')m(-OH)n(-O_2C(CH_2)_pCH_3)q$  [ $G$  = branched or straight C3-5-carbon chain and  $(-O_2CR')$ ,  $(-OH)$  and  $(-O_2C(CH_2)_pCH_3)$  are attached to any available carbon atom along  $G$ ;  $m = 1 - 4$ ;  $n = 0 - 3$ ;  $p = 0 - 16$ ;  $q = 0 - 3$ ; where  $m + n + q = 3$  or  $4$ ; and  $-O_2CR'$  is a fragment of a compound I wherein  $W = W1, W2, W3$ ;  $X = O, S, SO_2, CHR_5, , CHR5O, CHR5S, CHR5SO_2, CHR5CO, CH_2CHR_5$ ;  $Y = \text{bond}, CHR_6$ ;  $Z = \text{aryl}, \text{heteroaryl}$ ;  $R1 = H, \text{alkyl}, \text{alkenyl}$ ;  $R2 = H, \text{alkyl}, \text{aryl}, \text{arylalkyl}, \text{heteroarylalkyl}, \text{alkenyl}$ ;  $R3, R4 = H, \text{halo}, CF_3, CN, \text{alkyl}, \text{alkoxy}$ ;  $R5, R6 = H, \text{alkyl}, \text{aryl}, \text{alkenyl}, CN, CN4R9A$  (tetrazole),  $CO_2R9A, CONR9AR9B, CONR9AOR9B$ ;  $A = CH, N$ ;  $B = O, S$ ; wherein  $R1, R2, R5, R6, R7, R8 = \text{alkyl}, \text{aryl}, \text{alkenyl}, \text{arylalkyl}, \text{heteroarylalkyl}, \text{alkoxy}, \text{aryloxy}$  and each may be substituted with 1 - 3 hydrogen bonding groups]. Thus, 3-[(5-chloroindolecarbonyl)amino]-3,4-dihydrocarbostyril I ( $R1 = R2 = H, W = 5\text{-chloroindole}, X = CH_2, YZ = \text{benzo}$ ) was prepared from 3-amino-3,4-dihydrocarbostyril via acylation with 5-chloroindolecarboxylic acid resin-bound 2,3,5,6-tetrafluorophenyl ester. Further provided are pharmaceutical **comps.** and methods for treating diabetes and related diseases employing compds. above, either alone or in combination with another therapeutic agent.


IT 81093-37-0, Pravastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(companion therapeutic agent (lipid-lowering); preparation of triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compds.)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta, \delta, 6$ -trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 5 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:550886 HCAPLUS

DOCUMENT NUMBER: 141:94364

TITLE: **Compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors**

INVENTOR(S): Babcock, Walter Christian; Friesen, Dwayne Thomas; Smithey, Daniel Tod; Shanker, Ravi Mysore

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 168 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056395	A1	20040708	WO 2003-IB6170	20031218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004132771	A1	20040708	US 2003-678145	20031006 <--
WO 2004056396	A1	20040708	WO 2003-IB6240	20031218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2002-435328P	P 20021220

AB A **composition** comprises (1) a solid amorphous adsorbate comprising a cholesteryl ester transfer protein (CETP) **inhibitor** and a substrate; and (2) an **HMG-CoA reductase**

**inhibitor** is disclosed. The solid amorphous adsorbate provides concentration enhancement of the CETP **inhibitor** relative to a control **composition** consisting essentially of the unadsorbed CETP **inhibitor** alone, resulting in improved bioavailability. A solid amorphous adsorbate was prepared from torcetrapib, fumed silica (Cab-O-Sil), and mixed with granules containing atorvastatin hemicalcium trihydrate, calcium carbonate, microcryst. cellulose, croscarmellose **sodium**, polysorbate, hydroxypropyl cellulose, and pregelatinized starch, and then pressed into 150 mg compacts. The resulting compacts each contained 32 mg torcetrapib and 3.2 mg atorvastatin trihydrate hemicalcium salt.


IT 81093-37-0, Pravastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**compns.** of cholesteryl ester transfer protein  
**inhibitors** and **HMG-COA reductase**  
**inhibitors**)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,  
( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 6 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:100987 HCAPLUS

DOCUMENT NUMBER: 140:151978

TITLE: **Composition** comprising a cholesterol absorption **inhibitor**, an **HMG-CoA reductase inhibitor** and a stabilizing agent

INVENTOR(S): Moore, William D.; Fitzpatrick, Shaun; Seiler, Christian; Saklatvala, Robert; Petts, Catherine R.; Cho, Wing-Kee Philip

PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK; Schering Corporation

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010993	A1	20040205	WO 2003-US22889	20030722
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,  
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,  
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
 TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2493076 AA 20040205 CA 2003-2493076 20030722  
 US 2004126423 A1 20040701 US 2003-625004 20030722 <--  
 EP 1531805 A1 20050525 EP 2003-771709 20030722

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003012933 A 20050712 BR 2003-12933 20030722

PRIORITY APPLN. INFO.: US 2002-398691P P 20020726  
 WO 2003-US22889 W 20030722

AB The instant invention provides a pharmaceutical **composition** comprised  
 of a cholesterol absorption **inhibitor** and an **HMG-  
 CoA reductase inhibitor**, one or more  
 anti-oxidants, microcryst. cellulose, hydroxypropyl methylcellulose,  
 magnesium stearate and lactose. The **composition** need not contain  
 ascorbic acid in order to obtain desirable stability. Tablets were prepared  
 containing ezetimibe, simvastatin and BHA.


IT **81093-37-0, Pravastatin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceuticals comprising a cholesterol absorption **inhibitor**  
 , an **HMG-CoA reductase inhibitor**  
 and a stabilizing agent)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-  
 trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,  
 ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 7 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:1007596 HCAPLUS

DOCUMENT NUMBER: 140:65183

TITLE: Oil-containing, orally administrable pharmaceutical  
**composition** for improved delivery of a  
 therapeutic agent

INVENTOR(S): Chen, Feng-Jing; Patel, Mahesh V.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Pat. Appl. 2002.32,171.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003235595	A1	20031225	US 2003-397969	20030325 <--
US 6267985	B1	20010731	US 1999-345615	19990630 <--
US 6309663	B1	20011030	US 1999-375636	19990817 <--
US 2001024658	A1	20010927	US 2000-751968	20001229 <--
US 6458383	B2	20021001		
US 2002032171	A1	20020314	US 2001-877541	20010608 <--
US 6761903	B2	20040713		
WO 2004087052	A2	20041014	WO 2004-US9120	20040325
WO 2004087052	A3	20041118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:  
 US 1999-345615 A2 19990630  
 US 1999-375636 A2 19990817  
 US 2000-751968 A2 20001229  
 US 2001-877541 A2 20010608  
 WO 2000-US18807 A 20000710  
 US 2003-397969 A 20030325

AB The present invention relates to oral pharmaceutical **compsns.** and methods for improved delivery of therapeutic agents, e.g., lipid-regulating agents. **Compsns.** of the present invention include a carrier, where the carrier contains a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the **composition** forms a clear, aqueous dispersion. The invention also pertains to methods for treating lipid disorders such as hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia by oral administration of the **compsns.** provided.

IT **81093-37-0, Pravastatin**


RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(oral **composition** containing triglyceride and surfactants for improved delivery of hydrophobic drugs)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR,SR,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 8 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:777602 HCAPLUS

DOCUMENT NUMBER: 139:296975

TITLE: Combination of a **HMG-CoA reductase inhibitor** and an insulin secretion enhancer

INVENTOR(S): Damon, Robert Edson; Hughes, Thomas Edward; Burkey, Bryan

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080070	A2	20031002	WO 2003-EP2978	20030321
WO 2003080070	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2479880	AA	20031002	CA 2003-2479880	20030321
US 2004002519	A1	20040101	US 2003-393798	20030321 <--
EP 1523316	A2	20050420	EP 2003-744834	20030321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008613	A	20050301	BR 2003-8613	20030324
PRIORITY APPLN. INFO.:			US 2002-366752P	P 20020322
			WO 2003-EP2978	W 20030321

AB The present invention relates to a combination pharmaceutical **composition** comprising as active ingredients (i) a **HMG-CoA reductase inhibitor** or a salt, (ii) (a) an insulin secretion enhancer or a salt or (b) an insulin sensitizer or a salt. Thus, capsules contained fluvastatin **sodium** 42.962, CaCO<sub>3</sub> 125.680, NaHCO<sub>3</sub> 4.000, microcryst. cellulose 114.440, pregelatinized starch 83.800, Mg stearate 21.00, and talc 18.860 mg, and water qs.

IT **81093-37-0, Pravastatin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination of **HMG-CoA reductase**




inhibitor and insulin secretion enhancer)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (1R,2R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 9 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:717761 HCAPLUS

DOCUMENT NUMBER: 139:235434

TITLE: **Compositions** containing insulin-secretion stimulant and a **HMG-CoA reductase inhibitor** for reducing blood glucose and cholesterol

INVENTOR(S): Freese, Lori M.; Gorham, Thomas R.; Wheeler-Davis, Jennifer A.

PATENT ASSIGNEE(S): Upsher-Smith Laboratories, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 9 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003171407	A1	20030911	US 2002-94004	20020307 <--
WO 2003075933	A1	20030918	WO 2003-US6937	20030306

W: CA

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: US 2002-94004 A 20020307

AB The invention provides a pharmaceutical **composition** which is a combination of an insulin-secretion stimulant and a **HMG-CoA reductase inhibitor**. Suitable insulin-secretion stimulants include the sulfonylurea drugs, and suitable **HMG-CoA reductase inhibitors** include the statin drugs. The **composition** may be formulated to provide extended-release characteristics of 1 or both of the active components. Also provided are methods for treating a diabetic patient by using a combination of an insulin-secretion stimulant and a **HMG-CoA reductase inhibitor**. Practice of the methods of the invention may result in the administration of fewer dosages to the patient. The invention also provides a pharmaceutical **composition** which is a combination of an antihyperglycemic drug,

particularly a biguanide compound, in combination with a **HMG-CoA reductase inhibitor**. Also provided are methods for treating a diabetic patient using a combination of an antihyperglycemic biguanide compound and a **HMG-CoA reductase inhibitor**.


IT 81131-70-6, Pravastatin sodium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(comps. containing insulin-secretion stimulant and **HMG-CoA reductase inhibitor** for reducing blood glucose and cholesterol)

RN 81131-70-6 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L22 ANSWER 10 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:492702 HCAPLUS

DOCUMENT NUMBER: 139:47580

TITLE: Combinations of hormone replacement therapy  
**composition(s)** and sterol absorption  
**inhibitor(s)** and treatments for vascular  
conditions in post-menopausal women

INVENTOR(S): Strony, John T.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S.  
Ser. No. 166,942.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003119796	A1	20030626	US 2002-247085	20020919 <--
US 2003105028	A1	20030605	US 2002-166942	20020611 <--
PRIORITY APPLN. INFO.:			US 2001-324118P	P 20010921
			US 2002-166942	A2 20020611
			US 2000-256875P	P 20001220
			US 2001-23295	A2 20011217

OTHER SOURCE(S): MARPAT 139:47580

AB The present invention provides **compns.**, therapeutic combinations and methods including: (a) at least one hormone replacement therapy **composition**; and (b) at least one sterol absorption **inhibitor** which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5 $\alpha$ -stanols.

IT 81093-37-0, **Pravastatin**


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combinations of hormone replacement therapy **composition(s)** and sterol absorption **inhibitor(s)** and treatments for vascular conditions in post-menopausal women)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 11 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:455033 HCAPLUS

DOCUMENT NUMBER: 139:41802

TITLE: Stabilized pharmaceuticals containing **HMG-CoA reductase inhibitors**

INVENTOR(S): Pflaum, Zlatko; Kerc, Janez

PATENT ASSIGNEE(S): LEK Pharmaceuticals D.D., Slovenia

SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U. S. Ser. No. 591,322.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003109584	A1	20030612	US 2002-298187	20021115 <--
US 6806290	B2	20041019		
US 6531507	B1	20030311	US 2000-591322	20000609 <--
ES 2215050	T3	20041001	ES 2000-931486	20000609
PRIORITY APPLN. INFO.:			US 2000-591322	A2 20000609
			EP 2000-931486	A 20000609

AB Lovastatin, **pravastatin**, simvastatin, mevastatin, atorvastatin, and derivs. and analogs thereof are known as **HMG-CoA reductase inhibitors** and are used as antihypercholesterolemic agents. The majority of them are produced by

fermentation using microorganisms of different species identified as species belonging to *Aspergillus*, *Monascus*, *Nocardia*, *Amycolatopsis*, *Mucor* or *Penicillium* genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a **HMG-CoA reductase**

**inhibitor** which is stabilized by forming a homogeneous **composition** with a buffering substance or a basifying substance. This homogeneous **composition** is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia. **Pravastatin Sodium** (5 g) with chromatog. purity 99.5% and pH 7.4 (1%)/7.7 (5%) was dissolved in MeOH (30 mL), and Na<sub>2</sub>CO<sub>3</sub> (10 mg, dissolved in 0.15 mL of water) was added and finally, EtOAc (400 mL containing 2% of water) was added. After 1 h the resulted crystals were filtered off, washed with fresh EtOAc (50 mL) and dried at 40° for 6 h in vacuo. The chromatog. purity of resulting crystals (4.3 g) was 99.6%.

IT 81093-37-0, Pravastatin 81131-70-6,

**Pravastatin sodium**


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(stabilized pharmaceuticals containing **HMG-CoA reductase inhibitors**)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 81131-70-6 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 12 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:196949 HCAPLUS

DOCUMENT NUMBER: 138:226745

TITLE: **HMG-CoA reductase inhibitors** stabilized by a buffer or basifying substance

INVENTOR(S): Pflaum, Zlatko; Kerc, Janez

PATENT ASSIGNEE(S): LEK Pharmaceuticals D.D., Slovenia

SOURCE: U.S., 12 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6531507	B1	20030311	US 2000-591322	20000609 <--
AU 2000049434	A5	20011217	AU 2000-49434	20000609
ES 2215050	T3	20041001	ES 2000-931486	20000609
US 2003109584	A1	20030612	US 2002-298187	20021115 <--
US 6806290	B2	20041019		
PRIORITY APPLN. INFO.:			EP 2000-931486	A 20000609
			US 2000-591322	A 20000609
			WO 2000-IB773	A 20000609

AB The present invention relates to a **HMG-CoA reductase inhibitor** which is stabilized by forming a homogeneous **composition** with a buffering substance or a basifying substance. This homogeneous **composition** is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia. **Pravastatin Na** is stabilized by addition of Na<sub>2</sub>CO<sub>3</sub>.

IT **81093-37-0, Pravastatin 81131-70-6, Pravastatin sodium**


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**HMG-CoA reductase inhibitors**  
stabilized by a buffer or basifying substance)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-

trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,  
( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 81131-70-6 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt,  
( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 13 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:133112 HCAPLUS

DOCUMENT NUMBER: 138:175886

TITLE: Oral pharmaceutical **composition** containing a combination of PPAR $\alpha$  and **HMG-CoA reductase inhibitor**

INVENTOR(S): Vanderbist, Francis; Deboeck, Arthur; Baudier, Philippe; Sereno, Antonio

PATENT ASSIGNEE(S): Galephar M/F, Belg.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013608	A1	20030220	WO 2002-BE135	20020807
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003013607	A1	20030220	WO 2001-BE147	20010907
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2456732	AA	20030220	CA 2002-2456732	20020807
EP 1414496	A1	20040506	EP 2002-766983	20020807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005032878	A1	20050210	US 2004-486219	20040908 <--
PRIORITY APPLN. INFO.:				
			WO 2001-BE133	W 20010807
			WO 2001-BE147	W 20010907
			WO 2002-BE135	W 20020807
AB	Disclosed is an oral pharmaceutical <b>composition</b> containing, in the same pharmaceutical form, effective amts. of a <b>HMG-CoA reductase inhibitor</b> derivative and of peroxisome proliferator activated receptor- $\alpha$ (PPAR $\alpha$ ), especially fenofibrate. Also described is the use of some inactive ingredients which allow to improve the dissoln. and/or bioavailability of the drugs from the said <b>composition</b> . A capsule containing simvastatin 20, fenofibrate 200, Gelucire 44/14 350, vitamin E TPGS 20, polyethylene glycol 6000 30, buthylhydroxyanisol 0.08 mg was prepared			
IT	<b>81093-37-0, Pravastatin</b> RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral pharmaceutical <b>composition</b> containing PPAR $\alpha$ , <b>HMG-CoA reductase inhibitor</b> , glyceride derivs., and other excipients)			
RN	81093-37-0 HCAPLUS			
CN	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR, $\delta$ R,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 14 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:133111 HCAPLUS

DOCUMENT NUMBER: 138:175885

TITLE: Oral pharmaceutical **composition** containing a combination of fenofibrate and a **HMG-CoA reductase inhibitor**

INVENTOR(S): Vanderbist, Francis; Deboeck, Arthur; Baudier, Philippe

PATENT ASSIGNEE(S): Galephar M/F, Belg.

SOURCE: PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013607	A1	20030220	WO 2001-BE147	20010907
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2456732	AA	20030220	CA 2002-2456732	20020807
WO 2003013608	A1	20030220	WO 2002-BE135	20020807
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1414496	A1	20040506	EP 2002-766983	20020807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				



IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
 US 2005032878 A1 20050210 US 2004-486219 20040908 <--  
 PRIORITY APPLN. INFO.: WO 2001-BE133 W 20010807  
 WO 2001-BE147 A 20010907  
 WO 2002-BE135 W 20020807


AB Disclosed is an oral pharmaceutical **composition** containing, in the same pharmaceutical form, effective amts. of a HMG-CoA **reductase inhibitor** derivative and of fenofibrate. Also described is the use of some inactive ingredients which allow to improve the dissoln. and/or bioavailability of the drugs from the said **composition**. A capsule containing simvastatin 20, fenofibrate 200, Gelucire 44/14 350, vitamin E TPGA 20, polyethylene glycol 30, butylhydroxyanisole 0.08 mg was formulated.

IT **81093-37-0, Pravastatin**  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oral pharmaceutical **composition** containing a combination of fenofibrate and a **HMG-CoA reductase inhibitor** with excipients)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 15 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:869578 HCAPLUS

DOCUMENT NUMBER: 137:358182

TITLE: Sustained release pharmaceutical **composition**  
 and method of releasing pharmaceutically active agent  
 INVENTOR(S): Shah, Rajen; Patel, Arun Parmanand; Sandry, Roy Thomas  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont. of U.S. Ser. No. 415,313.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002169145	A1	20021114	US 2002-100656	20020318 <--
PRIORITY APPLN. INFO.:			US 1998-155253P	P 19981014
			US 1999-415313	A1 19991008

AB The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical **compns.** which contain therapeutic amts. of a pharmaceutically active agent, hydroxypropyl Me cellulose and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average mol. weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average mol. weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average mol. weight ranging from 100,000 to 500,000.


IT **81093-37-0, Pravastatin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained release pharmaceutical **composition** and method of releasing pharmaceutically active agent)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 16 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:868726 HCAPLUS

DOCUMENT NUMBER: 137:358160

TITLE: Pharmaceutical **composition** comprising a **HMG-CoA reductase inhibitor**

INVENTOR(S): Hedge, Deepak; Kulkarni, Sushrut

PATENT ASSIGNEE(S): Biochemie Gesellschaft m.b.H., Austria

SOURCE: PCT Int. Appl., 13 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089788	A2	20021114	WO 2002-EP4891	20020503
WO 2002089788	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE, TR

EP 1392277 A2 20040303 EP 2002-735331 20020503  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
US 2004167085 A1 20040826 US 2004-476816 20040413 <--  
US 6911472 B2 20050628

PRIORITY APPLN. INFO.:

GB 2001-11077 A 20010504  
WO 2002-EP4891 W 20020503

AB A pharmaceutical **composition** comprising an **HMG-CoA reductase inhibitor**, i.e., a statin, as an active ingredient, and an aminosugar, as a pH adjusting (basifying) agent, is described. **Compns.** comprising dehydroepiandrosterone (DHEA), a desquamating agent selected from retinoids, acylated salicylic acid derivs. or **HMG-CoA reductase inhibitors**, and sugar derivs., and comprising germs for a koji-making raw material and monacolin K, are excluded. For example, tablets were obtained containing **pravastatin sodium** 10.00%, lactose (filler) 68.20%, microcryst. cellulose (filler) 13.50%, polyvinylpyrrolidone (binder) 0.50%, croscarmellose **sodium** (disintegrant) 6.00%, Mg stearate (lubricant) 1.00%, and Meglumine (pH adjusting agent) 0.80%. Tablets were stable for > 1 mo under normal environment humidity conditions.


IT 81093-37-0, Pravastatin 81131-70-6,  
**Sodium pravastatin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of tablets of **HMG-CoA reductase inhibitors** containing aminosugar as pH adjusting agent)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 81131-70-6 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L22 ANSWER 17 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:777650 HCAPLUS

DOCUMENT NUMBER: 137:299910

TITLE: Therapeutic combinations containing COX-2 inhibitors for cardiovascular and inflammatory diseases treatment

INVENTOR(S): Seibert, Karen; Keller, Bradley T.; Isakson, Peter C.; Krul, Elaine S.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 316 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078626	A2	20021010	WO 2002-US9346	20020328
WO 2002078626	A3	20040429		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2442328	AA	20021010	CA 2002-2442328	20020328
US 2003199482	A1	20031023	US 2002-107809	20020328 <--
EP 1435956	A2	20040714	EP 2002-725362	20020328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1527709	A	20040908	CN 2002-810210	20020328
JP 2005507854	T2	20050324	JP 2002-576894	20020328
US 2004186154	A1	20040923	US 2004-473045	20040506 <--
PRIORITY APPLN. INFO.:			US 2001-279239P	P 20010328
			WO 2002-US9346	W 20020328
AB The present invention provides therapeutic combinations and methods for				

treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises an ASBT **inhibitor** combined with COX-2 **inhibitor**. A further therapeutic combination comprises an ASBT **inhibitor**, a COX-2 **inhibitor** and an HMG Co-A **reductase inhibitor**.

Another therapeutic combination comprises a chromene COX-2 **inhibitor** and an HMG Co-A **reductase inhibitor**.

Thus, a tablet **composition** contained benzothiepine 5, celecoxib 20, lactose 54, microcryst. cellulose 15, HPMC 3, Croscarmellose sodium 2, and Mg stearate 1 mg/tablet.


IT 81093-37-0, Pravastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutic combinations containing COX-2 **inhibitors** for cardiovascular and inflammatory diseases treatment)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 18 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:574956 HCAPLUS

DOCUMENT NUMBER: 137:129904

TITLE: Combinations of peroxisome proliferator-activated receptor activators and sterol absorption **inhibitors** for treatment of vascular diseases

INVENTOR(S): Kosoglou, Teddy; Davis, Harry R.; Picard, Gilles Jean Bernard

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058732	A2	20020801	WO 2002-US2009	20020125
WO 2002058732	A3	20030703		
WO 2002058732	B1	20030912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,

MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,  
 SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,  
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2434682	AA	20020801	CA 2002-2434682	20020125
EP 1353696	A2	20031022	EP 2002-714773	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006654	A	20040225	BR 2002-6654	20020125
EP 1413331	A2	20040428	EP 2004-161	20020125
EP 1413331	A3	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004521893	T2	20040722	JP 2002-559066	20020125
EP 1541175	A2	20050615	EP 2005-3029	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003005692	A	20041025	ZA 2003-5692	20030723
ZA 2003005694	A	20041025	ZA 2003-5694	20030723
ZA 2003005693	A	20050209	ZA 2003-5693	20030723
NO 2003003355	A	20030725	NO 2003-3355	20030725
US 2005153952	A1	20050714	US 2004-998400	20041129 <--
PRIORITY APPLN. INFO.:				
			US 2001-264396P	P 20010126
			US 2001-323839P	P 20010921
			US 2001-264275P	P 20010126
			US 2001-264600P	P 20010126
			US 2001-323842P	P 20010921
			EP 2002-707500	A3 20020125
			EP 2002-714773	A3 20020125
			US 2002-57323	A3 20020125
			WO 2002-US2009	W 20020125
			US 2002-136968	A3 20020501

OTHER SOURCE(S): MARPAT 137:129904


AB The present invention provides **compsns.**, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor (PPAR) activator; and (b) at least one substituted azetidinone or substituted  $\beta$ -lactam sterol absorption **inhibitor** which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. A tablet contained azetidinone 10, lactose monohydrate 55, microcryst. cellulose 20, povidone 4, croscarmellose **sodium** 8, **sodium** lauryl sulfate 2, and magnesium stearate 1 mg. The tablet can be coadministered with a tablets containing a PPAR activator such as ezetimibe. Synthetic preparation of ezetimibe from fluorohenylazetidinone derivs. is described. The coadministration of 10 mg of ezetimibe with 200 mg of fenofibrate was well tolerated and caused a significant reduction in LDL-C as compared to either drug alone or placebo.

IT **81093-37-0, Pravastatin**  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combinations of peroxisome proliferator-activated receptor activators and sterol absorption **inhibitors** for treatment of vascular diseases)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 19 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:574955 HCAPLUS

DOCUMENT NUMBER: 137:129903

TITLE: Combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions

INVENTOR(S): Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauër, William

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058731	A2	20020801	WO 2002-US1196	20020125
WO 2002058731	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434436	AA	20020801	CA 2002-2434436	20020125
US 2003069221	A1	20030410	US 2002-57339	20020125 <--
EP 1385548	A2	20040204	EP 2002-707500	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006644	A	20040225	BR 2002-6644	20020125
EP 1413331	A2	20040428	EP 2004-161	20020125
EP 1413331	A3	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517919	T2	20040617	JP 2002-559065	20020125
EP 1541175	A2	20050615	EP 2005-3029	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003005692	A	20041025	ZA 2003-5692	20030723

ZA 2003005694	A	20041025	ZA 2003-5694	20030723
ZA 2003005693	A	20050209	ZA 2003-5693	20030723
NO 2003003358	A	20030912	NO 2003-3358	20030725
US 2004097482	A1	20040520	US 2003-639900	20030813 <--
US 2005153952	A1	20050714	US 2004-998400	20041129 <--
PRIORITY APPLN. INFO.:			US 2001-264275P	P 20010126
			US 2001-264396P	P 20010126
			US 2001-264600P	P 20010126
			US 2001-323842P	P 20010921
			US 2001-323839P	P 20010921
			EP 2002-707500	A3 20020125
			EP 2002-714773	A3 20020125
			US 2002-57323	A3 20020125
			US 2002-57646	A1 20020125
			WO 2002-US1196	W 20020125
			US 2002-136968	A3 20020501

OTHER SOURCE(S): MARPAT 137:129903  
GI



I

AB The present invention provides **compns.**, therapeutic combinations and methods including: (a) at least one sterol absorption **inhibitor** and (b) at least one cardiovascular agent different from the sterol absorption **inhibitor**, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prepared containing cardiovascular agents which can be coadministered with formulations containing, e.g., I. The preparation of I was given.


IT **81093-37-0, Pravastatin**  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combinations of azetidinone sterol absorption **inhibitor**(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.






L22 ANSWER 20 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:428761 HCAPLUS  
 DOCUMENT NUMBER: 137:11000  
 TITLE: Pharmaceutical **compositions** containing  
 angiotensin receptor blockers for treating sexual  
 dysfunction  
 INVENTOR(S): Sahota, Pritam Singh  
 PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen  
 Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043807	A2	20020606	WO 2001-EP13976	20011129
WO 2002043807	A3	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2430924	AA	20020606	CA 2001-2430924	20011129
AU 2002026365	A5	20020611	AU 2002-26365	20011129
EP 1353727	A2	20031022	EP 2001-995680	20011129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004514703	T2	20040520	JP 2002-545776	20011129
US 2002107236	A1	20020808	US 2001-8445	20011203 <--
US 2004087484	A1	20040506	US 2003-433189	20030624 <--
PRIORITY APPLN. INFO.:			US 2000-250540P	P 20001201
			WO 2001-EP13976	W 20011129

AB The present invention relates to methods of treating sexual dysfunction associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an **HMG-CoA reductase inhibitor**. A film-coated tablet contained valsartan 8.00, microcryst. cellulose 54.00, crospovidone 20.00, colloidal silica 1.50, magnesium stearate 4.5, and Diolack pale red 00F34899 7.00 mg.


IT 81093-37-0, **PRAVASTATin**  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (pharmaceutical **compns.** containing angiotensin receptor blockers  
 for treating sexual dysfunction)  
 RN 81093-37-0 HCAPLUS  
 CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-  
 trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,  
 ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 21 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN.  
 ACCESSION NUMBER: 2002:392237 HCAPLUS  
 DOCUMENT NUMBER: 136:401651  
 TITLE: Preparation of fused pyridine derivatives as  
**HMG-CoA reductase**  
**inhibitors**  
 INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S.  
 Ser. No. 875,218.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002061901	A1	20020523	US 2001-8154	20011204 <--
US 6620821	B2	20030916		
US 2002028826	A1	20020307	US 2001-875218	20010606 <--
US 2004024216	A1	20040205	US 2003-602753	20030624 <--
PRIORITY APPLN. INFO.:			US 2000-211594P	P 20000615
			US 2001-875218	A2 20010606
			US 2001-8154	A3 20011204
OTHER SOURCE(S):		MARPAT 136:401651		
GI				



AB The title compds. I and their pharmaceutically acceptable salts, esters, prodrug esters, and stereoisomers are claimed [wherein: Z = CH(OH)CH<sub>2</sub>CR<sub>7</sub>(OH)CH<sub>2</sub>CO<sub>2</sub>R<sub>3</sub> or corresponding pyranone lactone derivs.; n = 0, 1; x = 0, 1, 2, 3, or 4; y = 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH<sub>2</sub>)<sub>x</sub> and/or (CH<sub>2</sub>)<sub>y</sub> together with addnl. carbons form a 3 to 7 membered spirocyclic ring; R<sub>1</sub>, R<sub>2</sub> = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R<sub>3</sub> = H or lower alkyl; R<sub>4</sub> = H, halo, CF<sub>3</sub>, OH, alkyl, alkoxy, CO<sub>2</sub>H, (un)substituted NH<sub>2</sub>, cyano, (un)substituted CONH<sub>2</sub>, etc.; R<sub>7</sub> = H, alkyl]. The compds. are **HMG-CoA reductase inhibitors**, and are active in inhibiting cholesterol biosynthesis and modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol (no data). I are thus useful in treating hyperlipidemia and dyslipidemia, in hormone replacement therapy, and in treating hypercholesterolemia, hypertriglyceridemia and atherosclerosis, as well as Alzheimer's disease and osteoporosis. Preps. of several compds. are described. For instance, a multistep synthesis of fused pyridine derivative II is reported. Compds. I may be used in a manner similar to atorvastatin, **pravastatin**, simvastatin, etc. Combinations of compds. I with various other drugs are claimed, the latter being specified as certain pharmacol. classes, as **inhibitors** of specific enzymes, as (ant)agonists of specific receptors, and as numerous named drugs.


IT **81093-37-0, Pravastatin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(therapeutic **compns.** also containing; preparation of fused pyridine derivs. as **HMG-CoA reductase inhibitors**)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 22 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:184896 HCAPLUS

DOCUMENT NUMBER: 136:236854

TITLE: Medicinal **compositions** for administration of  
 N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-  
 2,2-dimethylpropanamide and **HMG-CoA**  
**reductase inhibitors**

INVENTOR(S): Kohama, Takafumi; Inaba, Toshimori

PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020009	A1	20020314	WO 2001-JP7438	20010829
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, SG, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001082541	A5	20020322	AU 2001-82541	20010829
CA 2420951	AA	20030228	CA 2001-2420951	20010829
EP 1314423	A1	20030528	EP 2001-961177	20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
NZ 524406	A	20040625	NZ 2001-524406	20010829
BR 2001013523	A	20040629	BR 2001-13523	20010829
RU 2246302	C2	20050220	RU 2003-105835	20010829
US 2002055533	A1	20020509	US 2001-943712	20010831 <--
JP 2002145774	A2	20020522	JP 2001-262600	20010831
ZA 2003001543	A	20040609	ZA 2003-1543	20030225
NO 2003000946	A	20030408	NO 2003-946	20030228
US 2004092571	A1	20040513	US 2003-702930	20031105 <--
PRIORITY APPLN. INFO.:			JP 2000-265082	A 20000901
			US 2000-230601P	P 20000906
			WO 2001-JP7438	W 20010829
			US 2001-943712	B1 20010831

AB Disclosed are medicinal **compns.** for administering  
 N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-  
 dimethylpropanamide or its pharmacol. acceptable salt and an **HMG**  
**-CoA reductase inhibitor** either at the same  
 time or sep. after a definite period of time. Blood lipid-lowering effect

of oral administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate (I) 30 and **pravastatin** 3 mg/kg in hamsters was examined Also, tablet containing I 30, **sodium pravastatin** 10, lactose 408, corn starch 50, and magnesium stearate 2 mg was formulated.

IT **81093-37-0, Pravastatin**


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(medicinal **compns.** for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and **HMG-CoA reductase inhibitors**)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **81131-70-6, Sodium pravastatin**


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(medicinal **compns.** for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and **HMG-CoA reductase inhibitors**)

RN 81131-70-6 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (BR, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na


REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 23 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:171683 HCAPLUS  
 DOCUMENT NUMBER: 136:205466  
 TITLE: Medicinal **compositions** containing  
**HMG-CoA reductase**  
**inhibitors** and angiotensin II receptor  
 antagonists for preventing or treating heart failure  
 INVENTOR(S): Lee, Tsung Ming; Lee, Bai-Ching; Su, Shen-Fang; Hsiao,  
 Chia-Ling; Chu, Chia-Wei  
 PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan  
 SOURCE: PCT Int. Appl., 35 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002017913	A1	20020307	WO 2001-JP7437	20010829
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001084413	A5	20020313	AU 2001-84413	20010829
JP 2002145770	A2	20020522	JP 2001-259399	20010829
CA 2420844	AA	20030228	CA 2001-2420844	20010829
EP 1314425	A1	20030528	EP 2001-963398	20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2003181500	A1	20030925	US 2003-374171	20030226 <--
US 2005059720	A1	20050317	US 2004-977645	20041029 <--
PRIORITY APPLN. INFO.:			JP 2000-260949	A 20000830
			WO 2001-JP7437	W 20010829
			US 2003-374171	A3 20030226
AB	Disclosed are medicinal <b>compns.</b> comprising an <b>HMG-CoA reductase inhibitor</b> selected from the group consisting of <b>pravastatin</b> , simvastatin, lovastatin, pitavastatin and ZD-4522, and an angiotensin II receptor antagonist optionally together with a calcium channel blocker. The preventive effect of administration of <b>pravastatin</b> 10, losartan 50, and amlodipine 5 mg/day for 6 mo on left ventricle hypertrophy in patients was examined			
IT	<b>81093-37-0, Pravastatin</b> RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medicinal <b>compns.</b> containing <b>HMG-CoA reductase inhibitors</b> and angiotensin II receptor antagonists for preventing or treating heart failure)			
RN	<b>81093-37-0 HCAPLUS</b>			
CN	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR, $\delta$ R,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.




IT 81131-70-6, Pravastatin sodium salt

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medicinal **compos.** containing **HMG-CoA**  
**reductase inhibitors** and angiotensin II receptor  
antagonists for preventing or treating heart failure)

RN 81131-70-6 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-  
trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt,  
( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 24 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:661287 HCAPLUS

DOCUMENT NUMBER: 135:216008

TITLE: P-glycoprotein modifier-containing medicinal  
**compositions** to be delivered to the large  
intestine

INVENTOR(S): Tanida, Norifumi; Goto, Takeshi; Kurosaki, Yuji

PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064253	A1	20010907	WO 2001-JP1546	20010301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001036009	A5	20010912	AU 2001-36009	20010301
EP 1260233	A1	20021127	EP 2001-908178	20010301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003158097	A1	20030821	US 2002-220551	20021121 <--
PRIORITY APPLN. INFO.:			JP 2000-57630	A 20000302
			WO 2001-JP1546	W 20010301


AB Disclosed are novel medicinal **compsns.** aiming at delivering a medicine to a specific site of the large intestine; and prepsns. for intestinal administration with the use of the same. P-glycoprotein enhancers and **inhibitors** in the **compsns.** allow specific drug delivery in the lower or upper intestine. A tablet was formulated containing betamethasone **sodium** phosphate 2, verapamil (as P-glycoprotein **inhibitor**) 1, crystalline cellulose 10, lactose 81, crospovidone 5, and Mg stearate 1 part was coated with a coating **composition** containing Eudragit E 7, ethanol 70, water 19.5, and talc 3.5 parts.

IT **81093-37-0, Pravastatin**  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (P-glycoprotein modifiers for drug delivery to intestine)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 25 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:31357 HCAPLUS  
 DOCUMENT NUMBER: 134:80814  
 TITLE: Cyclooxygenase **inhibitor** and HMG-CoA reductase **inhibitor** as



medicinal **compositions** for treating  
colorectal cancer

INVENTOR(S): Tanida, Norifumi; Goto, Takeshi; Tomizawa, Naoko  
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan  
SOURCE: PCT Int. Appl., 15 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002014	A1	20010111	WO 2000-JP4327	20000630
W: AU, CA, CN, ID, JP, KR, US, VN				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2373940	AA	20010111	CA 2000-2373940	20000630
EP 1197228	A1	20020417	EP 2000-942407	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6620834	B1	20030916	US 2002-19469	20020415 <--
PRIORITY APPLN. INFO.:			JP 1999-188408	A 19990702
			WO 2000-JP4327	W 20000630


AB Medicinal **compns.** for colorectal cancer to be administered to the large intestine by taking advantage of prepns. disintegrating in the large intestine, characterized by containing a cyclooxygenase **inhibitor** and an **HMG-CoA reductase inhibitor**. These **compns.** are appropriate for inhibiting the postoperative liver metastasis and recurrence of colorectal cancer.

IT **81093-37-0, Pravastatin**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cyclooxygenase **inhibitor** and **HMG-CoA reductase inhibitor** as medicinal **compns.** for treating colorectal cancer)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 26 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:401689 HCAPLUS  
 DOCUMENT NUMBER: 131:49480  
 TITLE: Improved **HMG-CoA reductase inhibitor** extended release formulation  
 INVENTOR(S): Chen, Chih-ming; Chou, Joseph; Wong, David  
 PATENT ASSIGNEE(S): Andrx Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 28 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9930692	A1	19990624	WO 1998-US25766	19981204
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 5916595	A	19990629	US 1997-989253	19971212 <--
CA 2315329	AA	19990624	CA 1998-2315329	19981204
AU 9916275	A1	19990705	AU 1999-16275	19981204
AU 737962	B2	20010906		
EP 1035842	A1	20000920	EP 1998-960752	19981204
R: AT, CH, DE, ES, FR, GB, LI, PT, IE, FI				
JP 2002508311	T2	20020319	JP 2000-538675	19981204
US 2004029962	A1	20040212	US 2003-603254	20030625 <--
PRIORITY APPLN. INFO.:				
			US 1997-989253	A 19971212
			WO 1998-US25766	W 19981204
			US 1999-339494	B1 19990624
			US 1999-435576	A1 19991108
AB	A controlled release dosage formulation is described which is based on a combination of: (a) a compressed tablet core which contains an alkyl ester of a hydroxy-substituted naphthalene derivative, a pharmaceutically acceptable, water-swallowable polymer and an osmotic agent; and (b) an outer coating layer which completely covers the osmotic core and comprises a pH-sensitive coating agent and a water-insol. polymer. A tablet core containing lovastatin 11.99, Polyox WSR Coagulant 4.50, Polyox WSR N-80 17.98, lactose (anhydrous) 50.65, Na lauryl sulfate 3.00, fumed silica 0.45, and Myvaplex 600 1.80 %, was coated with a seal-coating <b>composition</b> containing Opadry clear 2.81 and NaCl 0.93 %; an inner coating <b>compn</b> . containing hydroxypropyl Me cellulose phthalate 2.27, talc 0.78, acetyl tri-Bu citrate 0.22, and sugars 0.62 %; and an outer coating <b>compn</b> . containing cellulose acetate 1, Eudragit S100 0.34, triacetin 0.08, polyethylene glycol 0.09, and sugars 0.5 %.			
IT	<b>81093-37-0, Pravastatin</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (controlled-release tablets containing <b>HMG-CoA reductase inhibitors</b> )			
RN	81093-37-0 HCAPLUS			
CN	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-			

trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,  
(8R,8R,1S,2S,6S,8S,8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 27 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:113552 HCAPLUS

DOCUMENT NUMBER: 130:173009

TITLE: Combinations of **HMG-CoA reductase inhibitors** and nicotinic acid and methods for treating hyperlipidemia

INVENTOR(S): Bova, David J.; Dunne, Josephine

PATENT ASSIGNEE(S): Kos Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906046	A1	19990211	WO 1998-US15989	19980731
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2001006644	A1	20010705	US 1997-903871	19970731 <--
CA 2297764	AA	19990211	CA 1998-2297764	19980731
AU 9886800	A1	19990222	AU 1998-86800	19980731
EP 1003515	A1	20000531	EP 1998-938227	19980731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9815549	A	20040622	BR 1998-15549	19980731
NO 2000000407	A	20000316	NO 2000-407	20000127
PRIORITY APPLN. INFO.:			US 1997-903871	A 19970731
			WO 1998-US15989	W 19980731
AB			The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixts. thereof in an extended release form and an <b>HMG-</b>	

**CoA reductase inhibitor**, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an **HMG-CoA reductase inhibitor** for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixts. thereof, and (3) a swelling agent to form a sustained release **composition** for extended release of the nicotinic acid or nicotinic acid compound or mixts. thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a **composition** for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl Me cellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an **HMG-CoA reductase inhibitor** in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compds. to provoke flushing reactions in individuals.

IT 81093-37-0, **Pravastatin**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral dosage forms containing **HMG-CoA reductase inhibitors** and nicotinate for treating hyperlipidemia)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, ( $\beta$ R, $\delta$ R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:


11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 28 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN.

ACCESSION NUMBER: 1998:98321 HCAPLUS  
 DOCUMENT NUMBER: 128:196661  
 TITLE: Antithrombotic and antiatherogenic pharmaceutical  
 composition including a thienopyridine  
 derivative and an HMG-CoA  
 reductase inhibitor  
 INVENTOR(S): Daste, Georges; Herbert, Jean-Marc  
 PATENT ASSIGNEE(S): Sanofi, Fr.  
 SOURCE: PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804259	A1	19980205	WO 1997-FR1353	19970721
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2751540	A1	19980130	FR 1996-9474	19960726
FR 2751540	B1	19981016		
ZA 9706247	A	19990115	ZA 1997-6247	19970715
CA 2261099	AA	19980205	CA 1997-2261099	19970721
CA 2261099	C	20030415		
AU 9738526	A1	19980220	AU 1997-38526	19970721
AU 725949	B2	20001026		
EP 914124	A1	19990512	EP 1997-935593	19970721
EP 914124	B1	20040121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9710560	A	19990817	BR 1997-10560	19970721
CN 1228698	A	19990915	CN 1997-197539	19970721
CN 1109547	B	20030528		
JP 2000500781	T2	20000125	JP 1998-508545	19970721
JP 3553610	B2	20040811		
NZ 333826	A	20000929	NZ 1997-333826	19970721
RU 2176504	C2	20011210	RU 1999-103623	19970721
EE 3853	B1	20021015	EE 1999-28	19970721
AT 258052	E	20040215	AT 1997-935593	19970721
PT 914124	T	20040531	PT 1997-935593	19970721
ES 2214632	T3	20040916	ES 1997-935593	19970721
CZ 294664	B6	20050216	CZ 1999-176	19970721
PL 188739	B1	20050429	PL 1997-331339	19970721
KR 2000029484	A	20000525	KR 1999-700501	19990122
US 6218403	B1	20010417	US 1999-230299	19990122 <--
NO 9900321	A	19990322	NO 1999-321	19990125
HK 1019405	A1	20031017	HK 1999-104578	19991101
PRIORITY APPLN. INFO.:			FR 1996-9474	A 19960726
			WO 1997-FR1353	W 19970721
OTHER SOURCE(S):	MARPAT 128:196661			
GI				



AB A pharmaceutical **composition** containing (a) a thienopyridine derivative (I; R = H, Cl-4 alkoxy carbonyl) or a pharmaceutically acceptable salt thereof; and (b) an **HMG-CoA-reductase inhibitor**, is disclosed. A combination of 5 mg/kg clopidogrel and 5 mg/kg simvastatin had synergistic effect and inhibited the formation of thrombose by 72% in rabbits. A 2-layered pharmaceutical tablet contained ticlopidine hydrochloride 200.00, microcryst. cellulose 69.88, maize starch 31.20, polyvidone 6.24, citric acid 3.12, stearic acid 0.78, magnesium stearate 0.78 mg in the first layer and simvastatin 20.00, butyldroxanisole 0.04, ascorbic acid 5.00, citric acid 2.50, microcryst. cellulose 10.00, maize starch 20.00, lactose 141.50, magnesium stearate 1.00, methylhydroxy Pr cellulose 1.65, hydroxypropyl cellulose 1.65, titanium dioxide 1.50, talc 0.60, yellow ferric oxide 0.092, and red ferric oxide 0.023 mg in the second layer.

IT **81131-70-6, Pravastatin Sodium**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antithrombotic and antiatherogenic pharmaceutical **composition** including thienopyridine derivative and **HMG-CoA reductase inhibitor**)

RN 81131-70-6 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (BR, $\delta$ R,1S,2S,6S,8S,8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 29 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:315691 HCAPLUS  
DOCUMENT NUMBER: 126:334419  
TITLE: Pharmaceutical **compositions** for preventing a second heart attack containing an **HMG CoA reductase inhibitor**  
INVENTOR(S): Olukotun, Adeove Y.; Alexander, John C.  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
SOURCE: U.S., 8 pp., Cont.-in-part of U.S. Ser. No. 824,679, abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5622985	A	19970422	US 1995-424984	19950419 <--
CA 2172884	AA	19961020	CA 1996-2172884	19960328
EP 738512	A1	19961023	EP 1996-106104	19960418
EP 738512	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AU 9650741	A1	19961031	AU 1996-50741	19960418
AU 715181	B2	20000120		
AT 244006	E	20030715	AT 1996-106104	19960418
PT 738512	T	20031128	PT 1996-106104	19960418
ES 2202393	T3	20040401	ES 1996-106104	19960418
JP 08291082	A2	19961105	JP 1996-98084	19960419

## PRIORITY APPLN. INFO.:

US 1990-536367	B1	19900611
US 1992-824679	B2	19920123
US 1995-424984	A	19950419

- AB A pharmaceutical **compns.** is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an **HMG CoA reductase inhibitor** such as pravastatin (I), alone or in combination with an ACE inhibitor. A tablet contained I-7, lactose 67, microcryst. cellulose 20, croscarmellose **sodium** 2, magnesium stearate 2, and magnesium oxide 3 parts.
- IT **81093-37-0, Pravastatin**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical **compns.** for preventing second heart attack containing **HMG CoA reductase inhibitor**)
- RN 81093-37-0 HCAPLUS  
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (8R,8R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 30 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:178769 HCAPLUS

DOCUMENT NUMBER: 126:176899

TITLE: Synergistic combination comprising an insulin sensitizer and a **HMG-CoA reductase inhibitor** for treating arteriosclerosis

INVENTOR(S): Tsujita, Yoshio; Horikoshi, Hiroyoshi; Shiomi, Masashi; Ito, Takashi

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 753298	A1	19970115	EP 1996-304924	19960703
EP 753298	B1	20011121		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2180296	AA	19970104	CA 1996-2180296	19960702
NO 9602784	A	19970106	NO 1996-2784	19960702
AU 9656261	A1	19970116	AU 1996-56261	19960702
AU 706628	B2	19990617		
JP 09071540	A2	19970318	JP 1996-172137	19960702
JP 3651816	B2	20050525		
US 5798375	A	19980825	US 1996-676090	19960702 <--
IL 118778	A1	19990714	IL 1996-118778	19960702
RU 2158607	C2	20001110	RU 1996-112769	19960702
TW 474809	B	20020201	TW 1996-85107984	19960702
ZA 9605650	A	19970127	ZA 1996-5650	19960703
CN 1148492	A	19970430	CN 1996-112170	19960703
CN 1089584	B	20020828		
CZ 286832	B6	20000712	CZ 1996-1982	19960703
AT 209046	E	20011215	AT 1996-304924	19960703
ES 2165474	T3	20020316	ES 1996-304924	19960703
PT 753298	T	20020328	PT 1996-304924	19960703
US 6159997	A	20001212	US 1998-61446	19980416 <--
HK 1011928	A1	20020628	HK 1998-113080	19981210
JP 2004075691	A2	20040311	JP 2003-359698	20031020
JP 2004250455	A2	20040909	JP 2004-96229	20040329
PRIORITY APPLN. INFO.:			JP 1995-167291	A 19950703



JP 1996-172137

A3 19960702

US 1996-676090

A3 19960702

AB A combination of 1 or more HMG-CoA reductase **inhibitors** (e.g., **pravastatin**, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with 1 or more insulin sensitizers (e.g., troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminoxy]ethoxy}benzyl}thiazolidine-2,4-dione) exhibits a synergistic effect and is better at prevention and/or treatment of arteriosclerosis and/or xanthoma than is either of the components of the combination alone. Thus, **pravastatin sodium** 0.5, troglitazone 20, Crospovidone 1.5, and Na lauryl sulfate 0.2 g were blended and the mixture was divided among 100 capsules, each containing 5 mg **pravastatin sodium** and 200 mg troglitazone. The preparation of some thiazolidine-2,4-diones is reported.

IT 81093-37-0, Pravastatin 81131-70-6,

**Pravastatin sodium**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synergistic **composition** containing insulin sensitizer and **HMG-CoA reductase inhibitor** for treatment of arteriosclerosis)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (BR,SR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 81131-70-6 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ , $\delta$ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (BR,SR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L22 ANSWER 31 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1996:701531 HCAPLUS  
 DOCUMENT NUMBER: 125:339030  
 TITLE: Use of **HMG CoA reductase inhibitor** to prevent second heart attack  
 INVENTOR(S): Olukotun, Adeoye Y.; Alexander, John C.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: Eur. Pat. Appl., 11 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 738512	A1	19961023	EP 1996-106104	19960418
EP 738512	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5622985	A	19970422	US 1995-424984	19950419 <---
PRIORITY APPLN. INFO.:			US 1995-424984	A 19950419
			US 1990-536367	B1 19900611
			US 1992-824679	B2 19920123


AB A method is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an **HMG CoA reductase inhibitor** such as **pravastatin**, alone or in combination with an ACE **inhibitor**. Tablets were formulated containing **pravastatin** 7, lactose 67, microcryst. cellulose 20, croscarmellose **sodium** 2, magnesium stearate 1, and magnesium oxide 3 parts by weight

IT **81093-37-0, Pravastatin**  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (**HMG CoA reductase inhibitor** to prevent second heart attack and pharmaceutical **compns.** containing **HMG CoA reductase inhibitor** and other ingredients)

RN 81093-37-0 HCAPLUS  
 CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,

(BR,8R,1S,2S,6S,8S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 32 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:497325 HCAPLUS

DOCUMENT NUMBER: 125:151167

TITLE: A controlled release drug delivery device comprising two-layered core and coating

INVENTOR(S): Rork, Gerald S.; Pipkin, James D.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9619201	A1	19960627	WO 1995-US16530	19951218
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5582838	A	19961210	US 1994-363451	19941222 <--
CA 2206211	AA	19960627	CA 1995-2206211	19951218
AU 9644726	A1	19960710	AU 1996-44726	19951218
AU 693313	B2	19980625		
EP 801560	A1	19971022	EP 1995-943469	19951218
EP 801560	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
CN 1171048	A	19980121	CN 1995-196988	19951218
CN 1081916	B	20020403		
HU 77370	A2	19980330	HU 1997-1914	19951218
JP 11509829	T2	19990831	JP 1995-519938	19951218
SK 281224	B6	20010118	SK 1997-805	19951218
RU 2168330	C2	20010610	RU 1997-112378	19951218
PL 183615	B1	20020628	PL 1995-320792	19951218
CZ 290802	B6	20021016	CZ 1997-1895	19951218
AT 244001	E	20030715	AT 1995-943469	19951218
PT 801560	T	20031031	PT 1995-943469	19951218
ES 2201133	T3	20040316	ES 1995-943469	19951218
FI 9702586	A	19970617	FI 1997-2586	19970617

NO 9702880 A 19970620 NO 1997-2880 19970620  
 PRIORITY APPLN. INFO.: US 1994-363451 A 19941222  
 WO 1995-US16530 W 19951218

AB A device disclosed for the controlled delivery of a beneficial agent consisting of (1) a core comprising at least two layers, wherein at least one layer comprises a beneficial agent and a polymer which forms microscopic gel beads upon hydration and at least one layer which comprises a polymer which forms microscopic gel beads upon hydration; and (2) an impermeable, insol. coating which adheres to and surrounds the core and contains apertures which provide an area for the hydration and release of the microscopic gel beads. A two-layered core contained lovastatin (I) 40, Carbopol 974P 16, trisodium citrate 32, and lactose 16 mg/layer in the first layer and Avicel PH101 20, Carbopol 974P 8, trisodium citrate 16, and lactose 8 mg/layer in the second layer. The cores were coated with a solution of cellulose acetate butyrate 20, and triethylcitrate 3 parts in a solution of acetone:ethanol (3:1) and sprayed onto the cores to a thickness of 100µm and two holes were drilled in the face of the device. The release profile of the two layer device were significantly improved over the single composition core, in that the last 20% of I was released at a more constant rate and greater than 95% of the I content was released in <20 h.


IT 81093-37-0, Pravastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled release drug delivery device comprising two-layered core and coating)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,8,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s HMG-CoA reductase inhibitor

9504 HMG  
 101 HMGS  
 9528 HMG  
 (HMG OR HMGS)  
 41216 COA  
 918 COAS  
 41395 COA  
 (COA OR COAS)  
 82330 REDUCTASE  
 6290 REDUCTASES  
 83384 REDUCTASE  
 (REDUCTASE OR REDUCTASES)

480825 INHIBITOR  
494689 INHIBITORS  
766615 INHIBITOR

(INHIBITOR OR INHIBITORS)

L23 3098 HMG-COA REDUCTASE INHIBITOR  
~~(HMG (W) COA (W) REDUCTASE (W) INHIBITOR)~~

=> s l23 and composition

638314 COMPOSITION  
288523 COMPOSITIONS  
921226 COMPOSITION  
(COMPOSITION OR COMPOSITIONS)  
1351441 COMPN  
544323 COMPNS  
1655583 COMPN  
(COMPN OR COMPNS)

2095452 COMPOSITION  
(COMPOSITION OR COMPN)

L24 341 L23 AND COMPOSITION

=> s l24 and pravastatin sodium

2420 PRAVASTATIN  
1 PRAVASTATINS  
2420 PRAVASTATIN  
(PRAVASTATIN OR PRAVASTATINS)

989801 SODIUM  
34 SODIUMS  
989810 SODIUM  
(SODIUM OR SODIUMS)

222 PRAVASTATIN SODIUM  
(PRAVASTATIN (W) SODIUM)

L25 19 L24 AND PRAVASTATIN SODIUM

=> s l25 and impurity

154887 IMPURITY  
191116 IMPURITIES  
285990 IMPURITY  
(IMPURITY OR IMPURITIES)

L26 0 L25 AND IMPURITY

=> s l25 and py<=1998

18939279 PY<=1998  
L27 3 L25 AND PY<=1998

=> d l25 ibib abs hitstr tot

L25 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:451253 HCAPLUS

DOCUMENT NUMBER: 142:487543

TITLE: **Compositions**, kits, and methods for the treatment of conditions associated with elevated cholesterol levels using HMG CoA synthase and reductase and soluble fibers

INVENTOR(S): Moreyra, Abel Ennio; Koraym, Ashraft M.; Wilson, Alan Chaney; Carryl, Owen Rickford

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA; University of Medicine and Dentistry of New Jersey

SOURCE: PCT Int. Appl., 19 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046796	A2	20050526	WO 2004-US37427	20041108
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-518183P P 20031107

AB Disclosed herein are methods of treating a condition associated with elevated cholesterol levels are provided, comprising administering to a mammal in need of such treatment a safe and effective amount of a cholesterol biosynthesis inhibitor and a soluble fiber. Further disclosed herein are kits comprising a first **composition** comprising a cholesterol biosynthesis inhibitor selected from the group consisting of **HMG CoA reductase inhibitors**, HMG CoA synthase inhibitors, and mixts. thereof; and a second **composition** comprising a soluble fiber. Even further described are **compns.** comprising a cholesterol biosynthesis inhibitor selected from the group consisting of **HMG CoA reductase inhibitors**, HMG CoA synthase inhibitors, and mixts. thereof; and a soluble fiber. For example, the combination of simvastatin tablet and psyllium fiber powder had a good effect of lowering cholesterol level in males.

L25 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:92513 HCAPLUS

DOCUMENT NUMBER: 142:183433

TITLE: Stabilization of therapeutic agents using a carbonate salt of an amino acid in the presence of a saccharide and pharmaceutical **compositions**

INVENTOR(S): Lulla, Amar; Malhotra, Geena

PATENT ASSIGNEE(S): Cipla Limited, India

SOURCE: Brit. UK Pat. Appl., 35 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2404336	A1	20050202	GB 2003-17877	20030730
WO 2005011737	A2	20050210	WO 2004-GB3305	20040730
WO 2005011737	A3	20050421		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,			

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

## PRIORITY APPLN. INFO.:

GB 2003-17877

A 20030730

AB Therapeutic agents, which are degrade when present in a pharmaceutical formulation, may be stabilized by admixing a stabilizing agent comprising at least one carbonate salt of an amino acid, wherein, at least in the case where the therapeutic agent is a **HMG-CoA reductase inhibitor**, or an ACE inhibitor, the stabilizing agent is enhanced by further comprising one or more saccharides. The therapeutic agent susceptible to degradation may be selected from **HMG-CoA reductase inhibitors**, ACE inhibitors, antihistaminics, benzimidazoles and anti-viral agents, (including nucleoside reverse transcriptase inhibitors). The carbonate salt of the amino acid is preferably present as either the group I or II alkali or alkali earth metal salt thereof, and the amino acid is preferably selected from the group consisting of glycine, arginine and lysine. The saccharide is preferably selected from the group consisting of lactose, sucrose, glucose, mannitol, xylitol, maltitol, sorbitol and erythritol, either in anhydrous or hydrated form. Such combinations may be combined with a pharmaceutically acceptable carrier or excipient to provide a pharmaceutical formulation. Tablets were prepared from a dry mix containing quinapril-HCl, monosodium glycine carbonate, lactose and Crosspovidone. Binder solution, lubricants, and coatings were also used.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:58227 HCAPLUS

DOCUMENT NUMBER: 142:156266

TITLE: Novel compounds and **compositions** comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and their use in treating or preventing cardiovascular disease and other disorders

INVENTOR(S): Kutney, James P.; Pritchard, Haydn P.; Lukic, Tatjana

PATENT ASSIGNEE(S): Forbes Medi-Tech Inc., Can.

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005453	A2	<del>20050120</del>	WO 2004-CA999	20040709
WO 2005005453	A3	20050609		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

PRIORITY APPLN. INFO.:


US 2003-615456

A 20030709

OTHER SOURCE(S):

MARPAT 142:156266

GI



AB The present invention provides, in one aspect, novel compds. comprising sterols and/or stanols and a cholesterol biosynthesis inhibitors, having the following formulas  $\text{R}^2(\text{CH}_2)_n\text{CO}_2\text{R}$ ,  $\text{R}^2\text{R}$ ,  $\text{R}^2\text{COCO}_2\text{R}$ , I-III [R = sterol, stanol;  $\text{R}^2$  = cholesterol biosynthesis inhibitor with at least one free and reactive carboxyl group;  $\text{R}^3$  = cholesterol biosynthesis inhibitor with at least one free and reactive hydroxyl group;  $\text{R}^4$  = derived from ascorbic acid; X = H, biol. acceptable metal, alkaline earth metal; n = 1-5], including salts, solvates and prodrugs of thereof in treating or preventing cardiovascular disease and other disorders. In another aspect, the present invention provides **compns.** comprising at least one sterol and/or stanol ester and at least one cholesterol biosynthesis inhibitor. Also provided are methods of treating or preventing a variety of diseases, conditions and disorders by administering the compds. or **compns.** provided herein.

L25 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:995960 HCAPLUS

DOCUMENT NUMBER: 141:416027

TITLE: Combination comprising S-[2-([1-(2-ethylbutyl)cyclohexyl]carbonyl)amino)phenyl]  
 2-methylpropanethioate and a **HMG CoA reductase inhibitor**

INVENTOR(S): Urata, Yasuo; Hoshino, Shoji; Kawamura, Hitoshi;  
 Okamoto, Hiroshi; Furukawa, Noboru

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098583	A1	2004-11-18	WO 2004-US13633	20040430
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,			



SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

US 2005020668 A1 20050127 US 2004-835916 20040430  
PRIORITY APPLN. INFO.: US 2003-467418P P 20030502  
US 2003-471495P P 20030516  
US 2003-477372P P 20030610  
US 2004-534856P P 20040108

AB The invention provides a combination comprising (a) S-[2-([1-(2-ethylbutyl)cyclohexyl]carbonyl)amino]phenyl] 2-methylpropanethioate (I) or prodrug of the active form thereof, and (b) at least one **HMG CoA reductase inhibitor**. Also provided are a pharmaceutical **composition**, package, and a kit comprising the the active ingredients, as well as a method for treatment and prophylaxis of a cardiovascular disorder involving the use of the the active ingredients. Thus, the combination of I and a **HMG CoA reductase inhibitor** decreased the atherogenic index in rabbits on a high cholesterol diet.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:965104 HCAPLUS  
DOCUMENT NUMBER: 141:384361  
TITLE: Sugar intake-ability enhancer  
INVENTOR(S): Shimomura, Iichiro; Takagi, Toshiyuki  
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan  
SOURCE: PCT Int. Appl., 29 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096276	A1	20041111	WO 2004-JP6093	20040427
WO 2004096276	C2	<del>20050331</del>		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2003-123781 A 20030428  
JP 2004-12257 A 20040120

AB It is intended to provide a medicinal **composition** containing an **HMG-CoA reductase inhibitor** as the active ingredient which aims at: enhancing the ability to intake sugar into warm-blooded animal cells; treating diabetes; treating or preventing diabetic complications; treating or preventing diabetes or diabetic complications caused by insulin resistance syndrome, and so on. For example, tablets containing pravastatin Na were formulated.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:60308 HCAPLUS  
 DOCUMENT NUMBER: 140:99668  
 TITLE: Medicinal **composition** for mitigating blood lipid or lowering blood homocysteine containing **HMG-CoA reductase inhibitors** and pyridoxine compounds  
 INVENTOR(S): Kondo, Tatsuhito; Takagi, Ikuo; Nakayama, Masato; Torizumi, Yasuhiro  
 PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan  
 SOURCE: PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006919	A1	20040122	WO 2003-JP8674	20030708
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2492781	AA	20040122	CA 2003-2492781	20030708
JP 2004189716	A2	20040708	JP 2003-272681	20030710
PRIORITY APPLN. INFO.:			JP 2002-202121	A 20020711
			JP 2002-343586	A 20021127
			WO 2003-JP8674	W 20030708
AB	Disclosed is a safe drug for mitigating blood lipid and for reducing the amount of blood homocysteine. It is a medicinal <b>composition</b> containing an <b>HMG-CoA reductase inhibitor</b> and a pyridoxine compound. The effect of simvastatin in combination with pyridoxine hydrochloride on blood cholesterol in beagle dog was examined. A tablet containing simvastatin 1.67, pyridoxine hydrochloride 16.7, and other ingredients q.s. to 200 mg was prepared.			
REFERENCE COUNT:	13	THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L25 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:913007 HCAPLUS  
 DOCUMENT NUMBER: 139:386419  
 TITLE: Combination of an **HMG-CoA reductase inhibitor** and a nitrate ester  
 INVENTOR(S): Scaramuzzino, Giovanni  
 PATENT ASSIGNEE(S): Italy  
 SOURCE: PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094923	A1	20031120	WO 2003-EP4860	20030508
W: AE, AG, AL, AM, AT, <del>AU, AZ, BA</del> , BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1505986	A1	20050216	EP 2003-735372	20030508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			IT 2002-MI1012	A 20020513
			WO 2003-EP4860	W 20030508

OTHER SOURCE(S): MARPAT 139:386419

AB The present invention relates to the therapeutic combination of an **HMG-CoA reductase inhibitor** (statin) and a nitrate ester and is useful mainly for the preparation of medicaments for the prevention and treatment of coronary diseases as myocardial infarction and cerebrovascular diseases as stroke. Particularly, as a nitrate ester, a nitrate prodrug of aspirin, salicylic acid or vitamin E is used. The **compns.**, compared to single components, have the advantages to be without toxic effects, mainly due to statins, and to be more effective. The effect of combination of simvastatin and 2-acetyloxy-benzoic acid 3-nitroxymethylphenyl ester on blood chemical in rats was examined

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:717761 HCAPLUS

DOCUMENT NUMBER: 139:235434

TITLE: **Compositions** containing insulin-secretion stimulant and a **HMG-CoA reductase inhibitor** for reducing blood glucose and cholesterol

INVENTOR(S): Freese, Lori M.; Gorham, Thomas R.; Wheeler-Davis, Jennifer A.

PATENT ASSIGNEE(S): Upsher-Smith Laboratories, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 9 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003171407	A1	20030911	US 2002-94004	20020307
WO 2003075933	A1	20030918	WO 2003-US6937	20030306
W: CA				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2002-94004	A 20020307

AB The invention provides a pharmaceutical **composition** which is a combination of an insulin-secretion stimulant and a **HMG-CoA reductase inhibitor**. Suitable insulin-secretion stimulants include the sulfonylurea drugs, and suitable **HMG-CoA reductase inhibitors** include the statin drugs. The **composition** may be formulated to provide extended-release characteristics of 1 or both of the active components. Also provided are methods for treating a diabetic patient by using a combination of an insulin-secretion stimulant and a **HMG-CoA reductase inhibitor**. Practice of the methods of the invention may result in the administration of fewer dosages to the patient. The invention also provides a pharmaceutical **composition** which is a combination of an antihyperglycemic drug, particularly a biguanide compound, in combination with a **HMG-CoA reductase inhibitor**. Also provided are methods for treating a diabetic patient using a combination of an antihyperglycemic biguanide compound and a **HMG-CoA reductase inhibitor**.

L25 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:455033 HCAPLUS

DOCUMENT NUMBER: 139:41802

TITLE: Stabilized pharmaceuticals containing **HMG-CoA reductase inhibitors**

INVENTOR(S): Pflaum, Zlatko; Kerc, Janez

PATENT ASSIGNEE(S): LEK Pharmaceuticals D.D., Slovenia

SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U. S. Ser. No. 591,322.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003109584	A1	<del>20030612</del>	US 2002-298187	20021115
US 6806290	B2	20041019		
US 6531507	B1	20030311	US 2000-591322	20000609
ES 2215050	T3	20041001	ES 2000-931486	20000609
PRIORITY APPLN. INFO.:			US 2000-591322	A2 20000609
			EP 2000-931486	A 20000609

AB Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivs. and analogs thereof are known as **HMG-CoA reductase inhibitors** and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to *Aspergillus*, *Monascus*, *Nocardia*, *Amycolatopsis*, *Mucor* or *Penicillium* genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a **HMG-CoA reductase inhibitor** which is stabilized by forming a homogeneous

**composition** with a buffering substance or a basifying substance. This homogeneous **composition** is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia. **Pravastatin Sodium** (5 g) with chromatog. purity 99.5% and pH 7.4 (1%)/7.7 (5%) was dissolved in MeOH (30 mL), and Na<sub>2</sub>CO<sub>3</sub> (10 mg, dissolved in 0.15 mL of water) was added and finally, EtOAc (400 mL containing 2% of water) was added. After 1 h the resulted crystals were filtered off, washed with fresh EtOAc (50 mL) and dried at 40° for 6 h in vacuo. The chromatog. purity of resulting crystals (4.3 g) was 99.6%.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:368876 HCAPLUS

DOCUMENT NUMBER: 138:374167

TITLE: **HMG-CoA reductase inhibitor compositions** with content uniformity, and storage-stable solid preparations packed with zeolite

INVENTOR(S): Iwata, Yukiya; Ochiai, Naoya

PATENT ASSIGNEE(S): Taiyo Pharmaceutical Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003137778	A2	20030514	JP 2001-335390	20011031
PRIORITY APPLN. INFO.:			JP 2001-335390	20011031

OTHER SOURCE(S): MARPAT 138:374167

AB Title **compsns.** contain [HOCHR<sub>2</sub>CH<sub>2</sub>CH(OH)CH<sub>2</sub>CO<sub>2</sub>-]<sub>m</sub> (R<sub>1</sub>)<sub>m</sub>+ (R<sub>1</sub> = H, alkali metal, alkaline earth metal; R<sub>2</sub> = organic residue; m = 1, 2) and low-substituted hydroxypropyl cellulose (I), and the content uniformity is <25% according to the test of Japanese Pharmacopeia 14th edition. Also claimed are solid prepsns. containing the **HMG-CoA reductase inhibitors** and packed with zeolites. Thus, tablets containing pravastatin Na and I showed content uniformity 14.8%, vs. 29.88%, when carmellose Ca was used instead of I.

L25 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:196949 HCAPLUS

DOCUMENT NUMBER: 138:226745

TITLE: **HMG-CoA reductase inhibitors** stabilized by a buffer or basifying substance

INVENTOR(S): Pflaum, Zlatko; Kerc, Janez

PATENT ASSIGNEE(S): LEK Pharmaceuticals D.D., Slovenia

SOURCE: U.S., 12 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 6531507	B1	20030311	US 2000-591322	20000609
AU 2000049434	A5	20011217	AU 2000-49434	20000609
ES 2215050	T3	20041001	ES 2000-931486	20000609
US 2003109584	A1	20030612	US 2002-298187	20021115
US 6806290	B2	20041019		

PRIORITY APPLN. INFO.:

EP 2000-931486	A	20000609
US 2000-591322	A	20000609
WO 2000-IB773	A	20000609

AB The present invention relates to a **HMG-CoA reductase inhibitor** which is stabilized by forming a homogeneous **composition** with a buffering substance or a basifying substance. This homogeneous **composition** is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia. Pravastatin Na is stabilized by addition of Na<sub>2</sub>CO<sub>3</sub>.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:868726 HCAPLUS

DOCUMENT NUMBER: 137:358160

TITLE: Pharmaceutical **composition** comprising a **HMG-CoA reductase inhibitor**

INVENTOR(S): Hedge, Deepak; Kulkarni, Sushrut

PATENT ASSIGNEE(S): Biochemie Gesellschaft m.b.H., Austria

SOURCE: PCT Int. Appl., 13 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089788	A2	20021114	WO 2002-EP4891	20020503
WO 2002089788	A3	20021212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1392277	A2	20040303	EP 2002-735331	20020503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004167085	A1	20040826	US 2004-476816	20040413
US 6911472	B2	20050628		

PRIORITY APPLN. INFO.:

GB 2001-11077	A	20010504
WO 2002-EP4891	W	20020503

AB A pharmaceutical **composition** comprising an **HMG-CoA reductase inhibitor**, i.e., a statin, as an active ingredient, and an aminosugar, as a pH adjusting (basifying) agent, is described. **Compns.** comprising dehydroepiandrosterone (DHEA), a desquamating agent selected from retinoids, acylated salicylic acid derivs. or **HMG-CoA reductase**

**inhibitors**, and sugar derivs., and comprising germs for a koji-making raw material and monacolin K, are excluded. For example, tablets were obtained containing **pravastatin sodium** 10.00%, lactose (filler) 68.20%, microcryst. cellulose (filler) 13.50%, polyvinylpyrrolidone (binder) 0.50%, croscarmellose sodium (disintegrant) 6.00%, Mg stearate (lubricant) 1.00%, and Meglumine (pH adjusting agent) 0.80%. Tablets were stable for > 1 mo under normal environment humidity conditions.

L25 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:504607 HCAPLUS

DOCUMENT NUMBER: 137:93594

TITLE: Preparation of cyclobutene derivatives as agents for use in combination with **HMG-CoA**

**reductase inhibitors**

INVENTOR(S): Kohama, Takafumi; Inaba, Toshimori; Kurata, Hitoshi

PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan

SOURCE: PCT Int. Appl., 674 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051396	A1	<del>20020704</del>	WO 2001-JP11294	20011221
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
JP 2002255799	A2	20020911	JP 2001-391028	20011225
PRIORITY APPLN. INFO.:			JP 2000-395948	A 20001226
OTHER SOURCE(S):		MARPAT 137:93594		

GI



AB The title compds. I [R1 is cycloalkyl, aryl, etc.; R2 is cycloalkyl, aryl, heterocyclic ring, etc.; R3 and R4 are each hydrogen or the like; A is a group of the general formula Q1 (wherein R5 is hydrogen or the like; R6 is an amine residue or the like; X and Y are each oxygen or the like; and Z is a single bond or the like); G is alkylene or the like; and when the dotted line is a double bond, D is carbon atom and E is :NO, when the dotted line is a single bond, D is CH or the like and E is NH or the like] are prepared A pharmaceutical **composition** containing **HMG-CoA reductase inhibitor** and I is claimed. In hamsters fed feed containing 0.3% cholesterol and 10% coconut oil, the

administration of pravastatin at 0.01% (weight/weight) alone caused 26% increase

in high d. lipoprotein cholesterol; the combined administration of pravastatin and a cyclobutene derivative of this invention at 0.01% (weight/weight)

caused 41% increase in high d. lipoprotein cholesterol. A formulation containing **pravastatin sodium** and a compound of this invention is given.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:171683 HCAPLUS

DOCUMENT NUMBER: 136:205466

TITLE: Medicinal **compositions** containing **HMG-CoA reductase**

**inhibitors** and angiotensin II receptor

antagonists for preventing or treating heart failure

INVENTOR(S): Lee, Tsung Ming; Lee, Bai-Ching; Su, Shen-Fang; Hsiao, Chia-Ling; Chu, Chia-Wei

PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002017913	A1	20020307	WO 2001-JP7437	20010829
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001084413	A5	20020313	AU 2001-84413	20010829
JP 2002145770	A2	20020522	JP 2001-259399	20010829
CA 2420844	AA	20030228	CA 2001-2420844	20010829
EP 1314425	A1	20030528	EP 2001-963398	20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2003181500	A1	20030925	US 2003-374171	20030226
US 2005059720	A1	20050317	US 2004-977645	20041029
PRIORITY APPLN. INFO.:			JP 2000-260949	A 20000830
			WO 2001-JP7437	W 20010829
			US 2003-374171	A3 20030226

AB Disclosed are medicinal **compns.** comprising an **HMG-CoA reductase inhibitor** selected from the group consisting of pravastatin, simvastatin, lovastatin, pitavastatin and ZD-4522, and an angiotensin II receptor antagonist optionally together with a calcium channel blocker. The preventive effect of administration of pravastatin 10, losartan 50, and amlodipine 5 mg/day for 6 mo on left ventricle hypertrophy in patients was examined

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:903840 HCAPLUS

DOCUMENT NUMBER: 136:25125



TITLE: Stabilized pharmaceutical compositions of statin derivs. as **HMG-CoA reductase inhibitors**

INVENTOR(S): Pflaum, Zlatko; Kere, Janez

PATENT ASSIGNEE(S): Lek Pharmaceutical and Chemical Company D.D., Slovenia

SOURCE: PCT Int. Appl., 35 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001093860	A1	20011213	WO 2000-IB773	20000609
W: AE, AL, AM, AT, AU, <del>AZ</del> , BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412326	AA	20011213	CA 2000-2412326	20000609
AU 2000049434	A5	20011217	AU 2000-49434	20000609
EP 1292293	A1	20030319	EP 2000-931486	20000609
EP 1292293	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2004501121	T2	20040115	JP 2002-501433	20000609
AT 260101	E	20040315	AT 2000-931486	20000609
ES 2215050	T3	20041001	ES 2000-931486	20000609
RU 2246943	C2	20050227	RU 2002-134764	20000609
NO 2002005784	A	20021202	NO 2002-5784	20021202
BG 107360	A	20031128	BG 2002-107360	20021206
PRIORITY APPLN. INFO.:			EP 2000-931486	A 20000609
			US 2000-591322	A 20000609
			WO 2000-IB773	W 20000609

AB Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivs. and analogs thereof are known as **HMG-CoA reductase inhibitors** and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to *Aspergillus*, *Monascus*, *Nocardia*, *Amycolatopsis*, *Mucor* or *Penicillium* genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a **HMG-CoA reductase inhibitor** which is stabilized by forming a homogeneous composition with a buffering substance or a basifying substance. This homogeneous composition is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and

hyperlipidemia. Pravastatin Na is stabilized by addition of Na carbonate.  
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2000:677395 HCAPLUS  
 DOCUMENT NUMBER: 133:256826  
 TITLE: Coating agents for oral formulations containing  
**HMG-CoA reductase inhibitors**  
 INVENTOR(S): Usui, Fusao; Yada, Shuichi; Kawabata, Kiyoshi  
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000264846	A2	<del>20000926</del>	JP 1999-70089	19990316
PRIORITY APPLN. INFO.:			JP 1999-70089	19990316

AB Oral preps. containing **HMG-CoA reductase inhibitors**, basic compds., and water-soluble polymers, are coated with a **composition** containing hydroxypropyl Me cellulose acetate succinate and plasticizers, preferably tri-Et citrate. This invention coated preparation allows maintaining of drug blood concentration and prevents isomerization of the drug, e.g. pravastatin. Tablets were formulated containing pravastatin Na, lactose, Crospovidone, Mg aluminate metasilicate, hydroxypropyl cellulose, and Mg stearate. The tablets were coated with a solution containing hydroxypropyl Me cellulose acetate succinate 12.5, tri-Et citrate 2.5, and 70% ethanolic aqueous solution 85 parts.

L25 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1998:98321 HCAPLUS  
 DOCUMENT NUMBER: 128:196661  
 TITLE: Antithrombotic and antiatherogenic pharmaceutical  
**composition** including a thienopyridine derivative and an **HMG-CoA reductase inhibitor**  
 INVENTOR(S): Daste, Georges; Herbert, Jean-Marc  
 PATENT ASSIGNEE(S): Sanofi, Fr.  
 SOURCE: PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804259	A1	<del>19980205</del>	WO 1997-FR1353	19970721
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,			

GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
GN, ML, MR, NE, SN, TD, TG

FR 2751540	A1	19980130	FR 1996-9474	19960726
FR 2751540	B1	19981016		
ZA 9706247	A	19990115	ZA 1997-6247	19970715
CA 2261099	AA	19980205	CA 1997-2261099	19970721
CA 2261099	C	20030415		
AU 9738526	A1	19980220	AU 1997-38526	19970721
AU 725949	B2	20001026		
EP 914124	A1	19990512	EP 1997-935593	19970721
EP 914124	B1	20040121		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI

BR 9710560	A	19990817	BR 1997-10560	19970721
CN 1228698	A	19990915	CN 1997-197539	19970721
CN 1109547	B	20030528		
JP 2000500781	T2	20000125	JP 1998-508545	19970721
JP 3553610	B2	20040811		
NZ 333826	A	20000929	NZ 1997-333826	19970721
RU 2176504	C2	20011210	RU 1999-103623	19970721
EE 3853	B1	20021015	EE 1999-28	19970721
AT 258052	E	20040215	AT 1997-935593	19970721
PT 914124	T	20040531	PT 1997-935593	19970721
ES 2214632	T3	20040916	ES 1997-935593	19970721
CZ 294664	B6	20050216	CZ 1999-176	19970721
PL 188739	B1	20050429	PL 1997-331339	19970721
KR 2000029484	A	20000525	KR 1999-700501	19990122
US 6218403	B1	20010417	US 1999-230299	19990122
NO 9900321	A	19990322	NO 1999-321	19990125
HK 1019405	A1	20031017	HK 1999-104578	19991101

PRIORITY APPLN. INFO.:

FR 1996-9474	A	19960726
WO 1997-FR1353	W	19970721

OTHER SOURCE(S): MARPAT 128:196661  
GI



AB A pharmaceutical **composition** containing (a) a thienopyridine derivative (I; R = H, Cl-4 alkoxy carbonyl) or a pharmaceutically acceptable salt thereof; and (b) an **HMG-CoA-reductase inhibitor**, is disclosed. A combination of 5 mg/kg clopidogrel and 5 mg/kg simvastatin had synergistic effect and inhibited the formation of thrombose by 72% in rabbits. A 2-layered pharmaceutical tablet contained ticlopidine hydrochloride 200.00, microcryst. cellulose 69.88, maize starch 31.20, polyvidone 6.24, citric acid 3.12, stearic acid 0.78, magnesium stearate 0.78 mg in the first layer and simvastatin 20.00, butyldroxanisole 0.04, ascorbic acid 5.00, citric acid 2.50, microcryst. cellulose 10.00, maize starch 20.00, lactose 141.50, magnesium stearate

1.00, methylhydroxy Pr cellulose 1.65, hydroxypropyl cellulose 1.65, titanium dioxide 1.50, talc 0.60, yellow ferric oxide 0.092, and red ferric oxide 0.023 mg in the second layer.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:192587 HCAPLUS

DOCUMENT NUMBER: 126:258927

TITLE: Effects of low-dose **pravastatin sodium** on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year

AUTHOR(S): Harsch, Michael; Braesen, Jan Hinrich; Niendorf, Axel  
CORPORATE SOURCE: Institute Pathology, University Hamburg, Hamburg, 20246, Germany

SOURCE: Atherosclerosis (Shannon, Ireland) (1997), 128(2), 139-147

CODEN: ATHSBL; ISSN: 0021-9150

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The aim of this study was to evaluate the cholesterol-lowering and antiatherosclerotic effect of the **HMG-CoA reductase inhibitor pravastatin sodium** at a dosage comparable to human therapy. Twelve heterozygous WHHL rabbits (13 mo old) were fed 100 g per day of a low cholesterol (0.03%) enriched diet for 12 mo. Six of these animals also received **pravastatin sodium** at a daily dose of 1 mg/kg body weight (verum group). In the verum group, total plasma cholesterol levels were lower by 47% ( $P < 0.05$ ) and relative aortic plaque volume (% ratio of total plaque volume to the aortic lumen) was reduced by 78% ( $P < 0.05$ ), when compared to the control group. Plaque **composition** was analyzed at 30 cross-sectional levels of the entire aortic wall using a grid window. Compared to the control group, the plaque type, in terms of architecture and **composition**, was altered as follows: lesions in the verum group had no confluent atheromatous cores and showed a pattern of a diffuse mixture of the main plaque components with a decreased relative content of necrosis (-44%) and an increased relative content of smooth muscle cells (+19%), whereas the relative content of macrophage-derived foam cells and collagen were nearly unaffected. Furthermore, a similar plaque volume and type was observed in animals with comparable cholesterol profiles. There was no histol. evidence for structurally damaging effects of **pravastatin sodium** on the arterial wall. We conclude that **pravastatin sodium** reduces total plasma cholesterol levels in this animal model, thereby leading to smaller plaques and a different plaque type.

L25 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:178769 HCAPLUS

DOCUMENT NUMBER: 126:176899

TITLE: Synergistic combination comprising an insulin sensitizer and a **HMG-CoA reductase inhibitor** for treating arteriosclerosis

INVENTOR(S): Tsujita, Yoshio; Horikoshi, Hiroyoshi; Shiomi, Masashi; Ito, Takashi

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 24 pp.  
CODEN: EPXXDW

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 753298	A1	19970115	EP 1996-304924	19960703
EP 753298	B1	20011121		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2180296	AA	19970104	CA 1996-2180296	19960702
NO 9602784	A	19970106	NO 1996-2784	19960702
AU 9656261	A1	19970116	AU 1996-56261	19960702
AU 706628	B2	19990617		
JP 09071540	A2	19970318	JP 1996-172137	19960702
JP 3651816	B2	20050525		
US 5798375	A	19980825	US 1996-676090	19960702
IL 118778	A1	19990714	IL 1996-118778	19960702
RU 2158607	C2	20001110	RU 1996-112769	19960702
TW 474809	B	20020201	TW 1996-85107984	19960702
ZA 9605650	A	19970127	ZA 1996-5650	19960703
CN 1148492	A	19970430	CN 1996-112170	19960703
CN 1089584	B	20020828		
CZ 286832	B6	20000712	CZ 1996-1982	19960703
AT 209046	E	20011215	AT 1996-304924	19960703
ES 2165474	T3	20020316	ES 1996-304924	19960703
PT 753298	T	20020328	PT 1996-304924	19960703
US 6159997	A	20001212	US 1998-61446	19980416
HK 1011928	A1	20020628	HK 1998-113080	19981210
JP 2004075691	A2	20040311	JP 2003-359698	20031020
JP 2004250455	A2	20040909	JP 2004-96229	20040329
PRIORITY APPLN. INFO.:			JP 1995-167291	A 19950703
			JP 1996-172137	A3 19960702
			US 1996-676090	A3 19960702
AB	A combination of 1 or more HMG-CoA reductase inhibitors (e.g., pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with 1 or more insulin sensitizers (e.g., troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminoxy]ethoxy}benzyl)thiazolidine-2,4-dione) exhibits a synergistic effect and is better at prevention and/or treatment of arteriosclerosis and/or xanthoma than is either of the components of the combination alone. Thus, <b>pravastatin sodium</b> 0.5, troglitazone 20, Crospovidone 1.5, and Na lauryl sulfate 0.2 g were blended and the mixture was divided among 100 capsules, each containing 5 mg <b>pravastatin sodium</b> and 200 mg troglitazone. The preparation of some thiazolidine-2,4-diones is reported.			

=> d 127 ibib abs hitstr tot

L27 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:98321 HCAPLUS


DOCUMENT NUMBER: 128:196661

TITLE: Antithrombotic and antiatherogenic pharmaceutical **composition** including a thienopyridine derivative and an **HMG-CoA reductase inhibitor**

INVENTOR(S): Daste, Georges; Herbert, Jean-Marc

PATENT ASSIGNEE(S): Sanofi, Fr.  
 SOURCE: PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804259	A1	19980205	WO 1997-FR1353	19970721 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2751540	A1	19980130	FR 1996-9474	19960726 <--
FR 2751540	B1	19981016		
ZA 9706247	A	19990115	ZA 1997-6247	19970715
CA 2261099	AA	19980205	CA 1997-2261099	19970721 <--
CA 2261099	C	20030415		
AU 9738526	A1	19980220	AU 1997-38526	19970721 <--
AU 725949	B2	20001026		
EP 914124	A1	19990512	EP 1997-935593	19970721
EP 914124	B1	20040121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9710560	A	19990817	BR 1997-10560	19970721
CN 1228698	A	19990915	CN 1997-197539	19970721
CN 1109547	B	20030528		
JP 2000500781	T2	20000125	JP 1998-508545	19970721
JP 3553610	B2	20040811		
NZ 333826	A	20000929	NZ 1997-333826	19970721
RU 2176504	C2	20011210	RU 1999-103623	19970721
EE 3853	B1	20021015	EE 1999-28	19970721
AT 258052	E	20040215	AT 1997-935593	19970721
PT 914124	T	20040531	PT 1997-935593	19970721
ES 2214632	T3	20040916	ES 1997-935593	19970721
CZ 294664	B6	20050216	CZ 1999-176	19970721
PL 188739	B1	20050429	PL 1997-331339	19970721
KR 2000029484	A	20000525	KR 1999-700501	19990122
US <u>6218403</u>	B1	20010417	US 1999-230299	19990122
NO 9900321	A	19990322	NO 1999-321	19990125
HK 1019405	A1	20031017	HK 1999-104578	19991101
PRIORITY APPLN. INFO.:			FR 1996-9474	A 19960726
			WO 1997-FR1353	W 19970721
OTHER SOURCE(S):	MARPAT 128:196661			
GI				



AB A pharmaceutical **composition** containing (a) a thienopyridine derivative (I; R = H, Cl-4 alkoxy-carbonyl) or a pharmaceutically acceptable salt thereof; and (b) an **HMG-CoA-reductase inhibitor**, is disclosed. A combination of 5 mg/kg clopidogrel and 5 mg/kg simvastatin had synergistic effect and inhibited the formation of thrombose by 72% in rabbits. A 2-layered pharmaceutical tablet contained ticlopidine hydrochloride 200.00, microcryst. cellulose 69.88, maize starch 31.20, polyvidone 6.24, citric acid 3.12, stearic acid 0.78, magnesium stearate 0.78 mg in the first layer and simvastatin 20.00, butyldroxanisole 0.04, ascorbic acid 5.00, citric acid 2.50, microcryst. cellulose 10.00, maize starch 20.00, lactose 141.50, magnesium stearate 1.00, methylhydroxy Pr cellulose 1.65, hydroxypropyl cellulose 1.65, titanium dioxide 1.50, talc 0.60, yellow ferric oxide 0.092, and red ferric oxide 0.023 mg in the second layer.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:192587 HCAPLUS

DOCUMENT NUMBER: 126:258927

TITLE: Effects of low-dose **pravastatin**

**sodium** on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year  
Harsch, Michael; Braesen, Jan Hinrich; Niendorf, Axel  
Institute Pathology, University Hamburg, Hamburg, 20246, Germany

AUTHOR(S):  
CORPORATE SOURCE:

SOURCE: Atherosclerosis (Shannon, Ireland) (1997), 128(2), 139-147

CODEN: ATHSBL; ISSN: 0021-9150

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The aim of this study was to evaluate the cholesterol-lowering and antiatherosclerotic effect of the **HMG-CoA reductase inhibitor pravastatin sodium** at a dosage comparable to human therapy. Twelve heterozygous WHHL rabbits (13 mo old) were fed 100 g per day of a low cholesterol (0.03%) enriched diet for 12 mo. Six of these animals also received **pravastatin sodium** at a daily dose of 1 mg/kg body weight (verum group). In the verum group, total plasma cholesterol levels were lower by 47% ( $P < 0.05$ ) and relative aortic plaque volume (% ratio of total plaque volume to the aortic lumen) was reduced by 78% ( $P < 0.05$ ), when compared to the control group. Plaque **composition** was analyzed at 30 cross-sectional levels of the entire aortic wall using a grid window. Compared to the control group, the plaque type, in terms of architecture and **composition**, was altered as follows: lesions in the verum group had no confluent atheromatous cores and showed a pattern of a diffuse mixture of the main

plaque components with a decreased relative content of necrosis (-44%) and an increased relative content of smooth muscle cells (+19%), whereas the relative content of macrophage-derived foam cells and collagen were nearly unaffected. Furthermore, a similar plaque volume and type was observed in animals with comparable cholesterol profiles. There was no histol. evidence for structurally damaging effects of **pravastatin sodium** on the arterial wall. We conclude that **pravastatin sodium** reduces total plasma cholesterol levels in this animal model, thereby leading to smaller plaques and a different plaque type.

L27 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:178769 HCAPLUS

DOCUMENT NUMBER: 126:176899

TITLE: Synergistic combination comprising an insulin sensitizier and a **HMG-CoA reductase inhibitor** for treating arteriosclerosis

INVENTOR(S): Tsujita, Yoshio; Horikoshi, Hiroyoshi; Shiomi, Masashi; Ito, Takashi

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 753298	A1	19970115	EP 1996-304924	19960703 <--
EP 753298	B1	20011121		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2180296	AA	19970104	CA 1996-2180296	19960702 <--
NO 9602784	A	19970106	NO 1996-2784	19960702 <--
AU 9656261	A1	19970116	AU 1996-56261	19960702 <--
AU 706628	B2	19990617		
JP 09071540	A2	19970318	JP 1996-172137	19960702 <--
JP 3651816	B2	20050525		
US 5798375	A	19980825	US 1996-676090	19960702 <--
IL 118778	A1	19990714	IL 1996-118778	19960702
RU 2158607	C2	20001110	RU 1996-112769	19960702
TW 474809	B	20020201	TW 1996-85107984	19960702
ZA 9605650	A	19970127	ZA 1996-5650	19960703 <--
CN 1148492	A	19970430	CN 1996-112170	19960703 <--
CN 1089584	B	20020828		
CZ 286832	B6	20000712	CZ 1996-1982	19960703
AT 209046	E	20011215	AT 1996-304924	19960703
ES 2165474	T3	20020316	ES 1996-304924	19960703
PT 753298	T	20020328	PT 1996-304924	19960703
US 6159997	A	20001212	US 1998-61446	19980416
HK 1011928	A1	20020628	HK 1998-113080	19981210
JP 2004075691	A2	20040311	JP 2003-359698	20031020
JP 2004250455	A2	20040909	JP 2004-96229	20040329
PRIORITY APPLN. INFO.:			JP 1995-167291	A 19950703
			JP 1996-172137	A3 19960702
			US 1996-676090	A3 19960702

AB A combination of 1 or more HMG-CoA reductase inhibitors (e.g., pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with 1



or more insulin sensitizers (e.g., troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminoxy]ethoxy)benzyl}thiazolidine-2,4-dione) exhibits a synergistic effect and is better at prevention and/or treatment of arteriosclerosis and/or xanthoma than is either of the components of the combination alone. Thus, **pravastatin sodium** 0.5, troglitazone 20, Crospovidone 1.5, and Na lauryl sulfate 0.2 g were blended and the mixture was divided among 100 capsules, each containing 5 mg **pravastatin sodium** and 200 mg troglitazone. The preparation of some thiazolidine-2,4-diones is reported.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
299.92	653.93

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-43.80	-43.80

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:05:03 ON 09 AUG 2005